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Our 1st study assessed growth deficits in IUGR juvenile lambs and the benefits of 
treatment with adrenergic and inflammatory mediators. Growth metrics including 
bodyweight, rate of gain, and crown-rump length were diminished by placental 
insufficiency-induced IUGR through 2 mo. of age but were recovered by daily 
clenbuterol or curcumin supplementation. Body composition metrics indicated by 
bioelectrical impedance, proximate analysis, and loin size revealed that fat-free lean 
mass, specific muscle group sizes, and protein-to-fat ratios were reduced in 
unsupplemented IUGR lambs but recovered to or even past controls in clenbuterol-
supplemented lambs. From these findings, we conclude that IUGR impairs postnatal 
growth and body composition through the juvenile stage, but postnatal treatment with 
clenbuterol or curcumin effectively recovered some aspects of diminished growth and 
improved body composition in IUGR lambs. 
Our 2nd study determined whether IUGR-induced fetal programming previously 
observed in skeletal muscle glucose metabolism and pancreatic β cell function progressed 
in juvenile-aged offspring and whether postnatal adrenergic modification via daily 
clenbuterol injection improves these deficits. Juvenile IUGR lambs continued to exhibit 
   
reduced skeletal muscle glucose oxidation and glucose-stimulated insulin secretion 
(GSIS). Clenbuterol effects on glucose metabolism in IUGR muscle varied. In vivo 
hindlimb glucose uptake and oxidation were improved by clenbuterol, but ex vivo glucose 
uptake was not improved and ex vivo glucose oxidation was further reduced in 
clenbuterol-supplemented IUGR primary muscle. Clenbuterol also recovered GSIS in 
IUGR lambs. Thus, results suggest that IUGR adaptions in insulin-stimulated glucose 
metabolism progress through the juvenile age. Furthermore, clenbuterol supplementation 
is effective when administered daily but loses its effect when removed.  
Our 3rd study sought to determine the impact of stress on BIA-estimated body 
composition in neonatal IUGR-born lambs and in heat-stressed feedlot wethers. The BIA 
successfully detected changes in fat-free mass and fat-free soft tissue in IUGR neonatal 
lamb at 25 d of age and in heat-stressed wethers but not in IUGR lambs at 3 d of age. The 
BIA, however did not detect differences in nutrient or specific muscle group mass in 
either cohort. Thus, we conclude that BIA reasonably estimates stress-induced changes in 
lamb body composition, except in very young animals. 
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Chapter 1 
Literature Review 
 
Introduction  
 Maternofetal stress during critical windows of fetal development alters 
intrauterine conditions, restricts fetal and neonatal growth, and programs metabolic thrift 
due to the deficient nutritional environment in which fetal development occurs. Prenatal 
programing was first described by Hales and Barker (1992) in their “Thrifty Phenotype 
Hypothesis,” which states that a poor intrauterine environment causes adaptive 
developmental programming that leads to decreased birthweight and an increased risk of 
metabolic diseases in adulthood. Subsequently, researchers have strived to understand the 
underlying mechanisms for developmental programming of growth and metabolic 
deficits associated with low birthweight, but the gap in knowledge remains. Intrauterine 
growth restriction (IUGR) is the result of nutrient-sparing metabolic and growth 
adaptations by the fetus in response to prenatal stress. These adaptions aid fetal survival 
at the expense of less vital peripheral tissues such as skeletal muscle. This leads to 
disruptions in muscle growth, glucose metabolism, insulin signaling, and body 
composition, all of which contribute poor postnatal growth and metabolic health 
(Limesand et al., 2007a; Brown et al., 2015; Yates et al., 2016; Cadaret et al., 2018; 
Posont et al., 2018). Fetal adaptions that stem from IUGR continue to be evident 
throughout the neonatal stage by consistently reduced muscle mass and poor oxidative 
metabolism (Cadaret et al., 2018; Cadaret et al., 2019b; Cadaret et al., 2019c). Using a 
well-characterized IUGR ovine model, we have reported that previously identified fetal 
   2 
growth and metabolic pathologies persist in the neonate, but the progression of these 
deficits between the neonatal and juvenile growth stages are unclear, and there is limited 
information about potential avenues for postnatal treatment of IUGR pathologies. 
  
Intrauterine Growth Restriction  
Placental Insufficiency Induces IUGR 
Intrauterine conditions that result in IUGR elicit in utero fetal programming that 
impairs peripheral insulin sensitivity and insulin secretion. This impairment leads to an 
increased risk for early onset obesity, hypertension, and Type II diabetes later in life 
(Hales et al., 1991). Together, these adaptions lead to 18-fold greater likelihood of 
Metabolic Syndrome for IUGR-born individuals (Barker et al., 1993; Gatford et al., 
2010).  
Placental insufficiency can be the result of a multitude of different maternal 
factors related to stress, such as harsh environmental conditions for livestock and poor 
dietary lifestyle choices in humans and is the most common cause for IUGR (Yates et al., 
2018b). Placental insufficiently is characterized by changes in placental function and 
structure that reduce nutrient transfer to the fetus including 1) decreased placental oxygen 
permeability (Limesand et al., 2018), 2) reduced placental transporters for glucose and 
amino acids (Brown et al., 2011; Lin et al., 2014), and 3) poor vascularity and increased 
placental vasculature resistance (Baschat et al., 2001; Cheema et al., 2006). The effects of 
placental insufficiency on the fetus increase as the pregnancy progresses through the third 
trimester because the fetus increasingly outgrows the capacity of  the stunted placenta 
(Limesand et al., 2018). With the fetus nutritional needs inadequate for optimal 
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development, the fetus becomes increasingly hypoxemic and hypoglycemic (Yates et al., 
2018b). This in turn causes chronic fetal stress, which is characterized by increased 
secretion of catecholamines (norepinephrine and epinephrine) from the fetal adrenal 
medulla (Yates et al., 2014) and greater circulating inflammatory cytokines such as tumor 
necrosis factor α (TNFα) (Cadaret et al., 2019b) and Interleukin-6 (IL-6) (Raghupathy et 
al., 2011). Increased circulating norepinephrine and epinephrine in IUGR fetuses induces 
the redistribution of fetal blood flow and nutrients to vital organs such as the brain, heart, 
and lungs and away from less vital tissues such as skeletal muscle (Alexander et al., 
1987; Morrison, 2008). This redistribution decreases hindlimb blood flow by almost 50% 
(Rozance et al., 2018), ultimately decreasing nutrient availability for muscle growth and 
energy production. Diminished prenatal muscle mass contributes to low birthweight and 
furthermore is correlated with reduced percentage of lean mass later in life (Gibbs et al., 
2019; Gibbs et al., 2020). Greater circulating fetal catecholamines also decrease 
pancreatic islet development by reducing β cell mass (Limesand et al., 2005). This 
reduction in β cell mass impairs the secretion of insulin, and thus hypoinsulinemia is also 
present in IUGR fetuses (Leos et al., 2010; Macko et al., 2016a). Following parturition, 
nutrient and oxygen availability is restored and catecholamine and cytokine blood 
concentrations are less elevated. Consequently, IUGR neonates become transiently 
hyperinsulinemic, which causes the dangerous perinatal hypoglycemic condition in IUGR 
newborns (Camacho et al., 2017; Limesand et al., 2018) and necessitates glucose 
supplementation (Camacho et al., 2017).  
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IUGR Reduces Survival & Value in Livestock  
In all livestock species, IUGR increases neonatal mortality and morbidity due to 
diminished vigor at birth (Wu et al., 2006). Intrauterine growth restriction has been 
reported to occur in approximately 10% of livestock, but the frequency can increase 
substantially during certain conditions (Wu et al., 2006). Entire herds of livestock may be 
affected by IUGR during chronic heat stress events, forage toxicity, or environmental 
drought, whereas shorter-term stress events may only affect pregnant animals that are 
within certain critical windows for fetal development at the time of stress. Regardless, 
IUGR has far-reaching implications for animal welfare and economic sustainability due 
to the increase in perinatal death loss and the diminished health and vigor of surviving 
offspring (Mellor, 1983). Producers are even more economically impacted by poor 
growth performance and carcass merit in surviving IUGR offspring (Smith et al., 1995; 
Gardner et al., 1998). Livestock impacted by IUGR exhibit increased fat deposition and 
decreased muscle growth (Greenwood et al., 1998) leading to carcasses with smaller 
high-value cuts and increased fat trim (Greenwood et al., 2000). Increased visceral fat 
deposition is independent of reductions in muscle mass (Desai and Ross, 2011), the latter 
of which is limited by reduced muscle stem cell function (Yates et al., 2014; Posont et al., 
2018) and subsequent muscle fiber hypertrophy (Yates et al., 2016). Rather, increased 
adipose deposition is likely due to an upregulation of the adipogenic PPARγ pathway 
(Desai and Ross, 2011) and/or disruption of fatty acid mobilization, both of which can 
lead to increased circulating free fatty acids (Beard et al., 2018). Along with poor carcass 
merit, IUGR livestock have decreased growth efficiency and rates of gain, leading to the 
need for extended time on feed to reach optimal harvest weight (Hegarty and Allen, 
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1978; Gondret et al., 2005; De Blasio et al., 2007). As such, IUGR-born livestock 
compound the challenge described by Canton & Hess (2010) that results when body 
weight and age are the only available measurements to determine dietary rations and time 
of harvest for groups of livestock. Nutritional management decisions based on these 
limited criteria can lead to a wide variation in body composition under normal conditions 
but are particularity ineffective for IUGR-born animals. When nutrition is not reconciled 
with thrifty IUGR metabolic programming, increased fat-to-muscle ratios and wasted 
feed input occur (Wigmore and Stickland, 1983).  
Less-than-desirable body composition and product uniformity in IUGR livestock 
lead to costly merit and yield discounts for producers at harvest, which can impede 
economic sustainability of a production system (Boleman et al., 1998). On average, 
IUGR-born offspring cost the US livestock industry 8% of its total annual product, which 
includes death loss of over 3 million beef calves, 930,000 dairy calves, and 580,000 
lambs (Wu et al., 2006) and lost revenue of up to $12.1 billion each year (USDA, 2017).  
Despite the well-documented economic impact of IUGR, minimal advancements have 
been made toward prevention or treatment strategies to offset growth and metabolic 
deficits in IUGR-born livestock.  
 
Sheep Are a Valuable Model for IUGR 
Intrauterine growth restriction has a multi-factorial etiology that impacts 
essentially all mammalian species, and our understanding of IUGR has benefitted from 
the many different animal models used to study the associated pathologies and 
mechanisms (Beede et al., 2019). Early research in the field utilized smaller animals such 
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as rabbits and rodents models, but most of the recent advancements in our understanding 
of IUGR has been gained through the use of ovine models. Sheep prove to be an efficient 
and effective dual-purpose model for biomedical and agricultural intrauterine research 
due to relative similarities in fetal developmental milestones compared to both humans 
and beef cattle (Yates et al., 2011a; Yates et al., 2012a; Posont et al., 2018; Yates et al., 
2018b; Beede et al., 2019). The ovine fetus also tolerates in utero surgical and 
experimental manipulation, making sheep the ideal species for fetal research (Yates et al., 
2011a; Yates et al., 2012a; Posont et al., 2018; Yates et al., 2018b; Beede et al., 2019). 
Researchers have developed a multitude of techniques to induce fetal and placental 
growth restriction in order to develop models that best suit their research needs. 
PI-IUGR. Maternal hyperthermia-induced placental insufficiency (PI) is the most 
common and best-characterized sheep model for IUGR. To create this model, pregnant 
ewes are exposed to ambient temperatures of 40°C with a relative humidity of 35% 
during peak placental development from the 40th to the 95th day of gestational age (dGA) 
(Cadaret et al., 2019b). This model reliably and consistently stunts the placenta, causing 
up to a 60% reduction in fetal growth at term (Brown et al., 2015; Macko et al., 2016a; 
Limesand et al., 2018). It is important to note that placental stunting in this model is due 
to the natural development of poor placental vasculature and restricted placentome size 
rather than decreased number of placentomes, which leads to the increased fetal-to-
placenta mass ratio (Morrison, 2008). Reduced placental size combined with reductions 
in placental vasculature and nutrient transporters leads to the severity of this model, 
which can be controlled by the number of days for which ewes are exposed to 
hyperthermia (Galan et al., 2005).  
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MI-IUGR. Maternofetal inflammation (MI), a model recently developed in sheep 
by our lab, has been used to mimic the sustained inflammation associated with conditions 
such as obesity or illness during gestation (Cadaret et al., 2018; Posont et al., 2018; 
Cadaret et al., 2019b). It is created via serial maternal IV injections of the bacterial 
endotoxin, E.coli lipopolysaccharide (LPS), every 72 hours during the first 15 days of the 
3rd trimester (Cadaret et al., 2019b). This stimulates a chronic maternal and fetal 
inflammatory response that is marked by increased circulating leukocytes and Tumor 
Necrosis Factor alpha (TNFα) concentrations that persist well after LPS injections are 
discontinued (Cadaret et al., 2019b). As one response to maternofetal inflammation, 
fetuses near term exhibit an increase in skeletal muscle cytokine receptors and pathway 
sensitivity that appear to contribute to the impaired capacity for muscle growth and 
metabolism (Posont et al., 2018; Cadaret et al., 2019b). Growth restriction in this model 
(~24% fetal growth restriction at term) is typically less severe when compared to the 
maternal hyperthermia model, but metabolic deficiencies are similar (Beede et al., 2019).  
Over/Under Nutrition. Poor nutrition (excess or deficiency) during critical 
windows for placental and fetal development can stunt placental and fetal growth, 
although in some cases overnutrition causes fetal overgrowth (Caton and Hess, 2010) 
Two ovine models have been used to study the effects of maternal over and 
undernutrition, respectively, during gestation. The overnourished adolescent ewe model 
creates fetal growth restriction by supplying newly-pubertal ewes (made pregnant by 
embryo transfer) with 200% of the ewe’s normal dietary energy requirements (Carr et al., 
2012). This model causes placental insufficiency via decreased placental size rather than 
by reduced expression and activity of placental glucose and amino acid transporters 
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(Wallace et al., 2003). Placental insufficiency in this model is further compounded by 
increased nutrient demand of the growing adolescent dam, which also restricts nutrient 
availability for the fetus. In mature dams, however, the overnutrition model results in 
inconsistencies between fetal growth restriction and fetal overgrowth, making it difficult 
to model IUGR for research. At the other end of the spectrum, the nutrient restriction 
model is created by supplying pregnant ewes with only 60% of the ewe’s normal dietary 
energy requirements (Lemley et al., 2011). Implementation of long-term (i.e. early 
through late gestation) nutrient restriction reduces fetal weights by 10-20% without 
obvious effects on placental development or function (Wallace, 1948; Mellor and 
Murray, 1982; Lemley et al., 2011).  
Surgical Placental Reduction. Researchers also utilize surgical and mechanical 
techniques to reduce placental function and induce IUGR, which can offer more control 
of severity. The endometrial carunclectomy model involves the surgical removal of all 
but four of the 60 to 90 uterine caruncles prior to breeding. This reduces the number of 
placental attachment sites, which leads to diminished nutrient transfer and fetal growth 
restriction of ~26% (Zhang et al., 2016). Another surgical model uses single umbilical 
artery ligation (SUAL) performed in the last trimester to reduce umbilical blood flow and 
nutrient transfer, leading to fetal growth restriction of ~22% (Oh et al., 1975; 
Supramaniam et al., 2006). Finally, placental embolization can be created by embedding 
microspheres into the placental vasculature via placental capillary infusion, which leads 
to placental blood flow reduction, increased placental vasculature resistance, and fetal 
growth restriction of up to 66% (Lang et al., 2000; Bhide et al., 2016).   
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IUGR Pathologies: Reduced Growth Capacity & Metabolic Dysfunction  
When fetal nutrient demand is not met, the fetus must adapt its developmental 
trajectory in order to survive. Because they alter development, these adaptive 
programming mechanisms have life-long consequences on growth and metabolic 
function, and in IUGR-born offspring these adaptions increase the risk of life-threatening 
health deficits (Thorn et al., 2011; Camacho et al., 2017). Studies in PI-IUGR lambs 
show that offspring are hallmarked by consistently-exhibited pathologies, including 
reduced muscle mass, asymmetric growth patterns, impaired skeletal muscle glucose 
metabolism, and β-cell dysfunction (Limesand et al., 2007a; Limesand et al., 2018; Yates 
et al., 2018b). Nutrient-sparing developmental mechanisms that cause these pathologies 
are critical for maintaining vital organ growth and function even though it is at the 
expense of skeletal muscle, which normally accounts for as much as 85% of insulin-
stimulated glucose utilization (Brown, 2014). When nutrient supply is restricted, the 
growth of skeletal muscle facilitated by progenitor cells known as myoblasts is 
subsequently impaired. This is reflected in reduced myoblast function and decreased 
sensitivity of myogenic stimulation in IUGR-born offspring (Yates et al., 2014). Impaired 
hypertrophic muscle growth is evident in the near-term fetus (Yates et al., 2016) and the 
neonate (Posont et al., 2018; Cadaret et al., 2019b). In addition to myoblast dysfunction, 
protein degradation pathways are upregulated in IUGR fetuses, which mobilize amino 
acids to be used as energy substrates rather than for protein synthesis and accretion 
(Rozance et al., 2018). Restricted muscle growth is accompanied by increased glycolytic-
to-oxidative fiber proportions (Yates et al., 2016), reflecting a shift in muscle metabolism 
that favors glycolytic lactate production rather than glucose oxidation (Limesand et al., 
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2007a; Brown et al., 2015). This is supported by studies performed by our lab in which 
IUGR fetuses and neonates exhibited diminished skeletal muscle glucose oxidation 
independently of their capacity for glucose uptake or utilization (Cadaret et al., 2019b; 
Cadaret et al., 2019c; Posont, 2019). Glucose metabolism in IUGR offspring is further 
compromised by reduced pancreatic β-cell mass and islet function. Proper glucose-
stimulated insulin secretion from β-cells is critical for insulin-stimulated glucose 
metabolism and glucose homeostasis. However, IUGR pancreatic islets are characterized 
by decreased size and β-cell proliferation (Limesand et al., 2005), impaired development 
of islet microvasculature (Lee and Hennighausen, 2005; Kostromina et al., 2013), 
reduced islet insulin content (Limesand et al., 2006; Limesand et al., 2007a), and reduced 
capacity for glucose-stimulated insulin secretion (Limesand et al., 2006; Limesand et al., 
2007a). Adaptions affecting skeletal muscle growth and metabolism in the IUGR fetus 
contribute to poor later-life health, but it has yet to be determined how these pathologies 
progress between the neonatal and the juvenile stages and whether the latter is an 
effective window for postnatal intervention. 
 
Components of Body Composition 
Skeletal Muscle Development  
 Body composition is an important parameter of health in humans and livestock. In 
addition, body composition is also a determining factor in the carcass value of livestock. 
It is largely dependent on proper development of skeletal muscle and adipose tissues. 
Skeletal muscle is a dynamic tissue that not only facilitates structural movement of the 
body but also plays a key role in glucose homeostasis and metabolic efficiency (Brown, 
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2014). Skeletal muscle mass accounts for roughly 40% of body mass in humans and 50% 
of in livestock, and primarily consists of the muscles that make up the head, limbs, and 
trunk of the body (Gunn, 1989; Kim et al., 2016). Myogenesis is the multistep 
physiological process in which muscle develops during fetal development for most 
mammalian species, although it continues into the neonatal stage for some litter-bearing 
species (Bentzinger et al., 2012). Myogenesis involves sequential expression of a series 
of myogenic regulatory factors (MRF) that are transcription factors that specifically 
regulate myogenic gene expression responses (Soto et al., 2017). These factors also serve 
as biomarkers for regulating the progression of myoblast stages. This process is activated 
during embryonic development by signaling from surrounding tissue, primarily the 
dermomyotome or neural tube, and begins with the expression of paired box transcription 
factors including Pax 7 within certain somite cells (Buckingham and Relaix, 2015). These 
Pax 7+ cells migrate from the somite to muscle development sites in the embryo where 
cells proliferate until exiting the cell cycle for myogenic differentiation (Buckingham and 
Relaix, 2015). Pax 7+ expression is then co-expressed with the initial expression of 
myogenic factor 5 (Myf5) and the later expression of myogenic determining factor 1 
(MyoD) that mark these cells as muscle precursors (Du et al., 2010). The expression of 
Myf5 and MyoD resign these formerly multipotent cells to a myogenic fate by 
committing the cell into muscle stem cells or myoblasts (Haldar et al., 2008). 
Proliferating myoblasts exit the cell cycle following the increased expression of MyoD 
and myogenin, which signify terminal differentiation of the myoblast. Differentiated 
myoblasts are capable of fusion into multinucleated myofibers within early embryonic 
development (Edmondson and Olson, 1993). As myoblasts differentiate in preparation for 
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fusion, myoblasts begin production of desmin, a type III myofilament. Desmin 
contributes to the structural integrity and sarcomere development of myofibers (Li et al., 
1997) and is also a hallmark biomarker of fully-differentiated myoblasts. 
  
Skeletal Muscle Fiber Types  
 Skeletal muscle fibers can be classified in several ways. One common 
categorization is by their metabolic properties that correspond to the myosin heavy chain 
(MyHC) isoform that they express. In mammals, most skeletal muscle groups have 
heterogeneous populations of the three fiber types: Types I, IIa, and IIx, (IIb is the fourth 
fiber type observed in rodents). Fibers of different types are differentiated by contractile 
speed and metabolic function, and over time fibers can transition between types in order 
to maintain appropriate metabolic function (Pette and Staron, 1997; Brown, 2014). Type I 
fibers are slow twitch red fibers and contain elevated amounts of myoglobin that 
contribute to Type I high oxidative capacity. Type I fibers utilize oxidative 
phosphorylation as the primary pathway for metabolism, which is ideal for low-input, 
high duration contractile activity (Scott et al., 2001). Type IIx fibers are white, fast twitch 
fibers that rely primarily on glycolytic metabolism, providing power but are inefficient 
and highly susceptible to fatigue (Schiaffino and Reggiani, 2011).Type IIa fibers are fast 
twitch, red fibers that posess both glycolytic and oxidative metabolic capability. Type IIa 
fibers represent an intermediate form between Type I and Type IIx fibers and are the 
most dynamic regarding the utilization of energy sources during short duration, high 
contractile activity (Pette and Staron, 1990).  
 
   13 
Skeletal Muscle Growth 
 The completion of muscle hyperplasia prior to birth limits postnatal muscle 
growth to hypertrophy (i.e. increased diameter and length) of existing myofibers 
(Gollnick et al., 1981; White et al., 2010). Postnatal muscle growth (hypertrophy) 
requires the establishment of muscle stem cell populations during fetal myogenesis. A 
subset of myoblasts do not differentiate but rather become quiescent satellite cells 
(Schultz, 1989). These satellite cells migrate to the basal lamina of myofibers and remain 
in the quiescent state until activated (Collins et al., 2005). To facilitate muscle growth, 
quiescent satellite cells are activated and return to the cell cycle (i.e. proliferate), 
differentiate, and eventually fuse with existing muscle fibers (Gibson and Schultz, 1983; 
Collins et al., 2005; Zammit et al., 2006). This increases the fiber’s myonuclear content 
and thus its capacity for protein synthesis and growth. A subset of activated cells self-
renew the muscle stem cell pool following proliferation by again becoming quiescent 
satellite cells (Zammit et al., 2006). 
Protein cycling is the combined fluxes of protein synthesis and protein 
degradation that help to balance fiber size with nutrient availability. These fluxes are 
determined by nutrient levels, growth factors, and activity of skeletal muscle (Paul and 
Rosenthal, 2002; Lai et al., 2004). Skeletal muscle hypertrophy occurs when protein 
synthesis exceeds protein degradation, leading to structural protein accumulation (Adams 
and Haddad, 1996). Protein synthesis is particularly responsive to insulin and insulin 
growth factor I (IGF-I), which signal in part through mammalian target of rapamycin 
(mTOR)-mediated pathways (Vandenburgh et al., 1991; Rommel et al., 2001). When 
insulin or IGF-I bind to respective tyrosine kinase receptors on the plasma membrane of 
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muscle, it results in phosphorylation of insulin receptor substrate 1, which initiates the 
activation sequence of phosphoinositide 3-kinase and then protein kinase B (Akt) (Sandri 
et al., 2013). Akt stimulates mTOR complex 1 (mTORC-1), which in turn activates 
ribosomal protein S6 kinase to increase protein synthesis and thus myofiber growth 
(Bodine et al., 2001; Rommel et al., 2001). mTORC-1 also inhibits kinases involved in 
muscle protein degradation (Zhang et al., 2014). Protein degradation is a mechanism for 
providing amino acids as substrates for metabolism when availability of carbohydrates or 
fatty acids is diminished. It is primarily facilitated by the ubiquitin proteasome pathway 
that marks proteins for degradation by attaching ubiquitin chains (Rock et al., 1994). This 
“flagging” step initiates the ATP-dependent catabolic reactions that break down large 
proteins into small peptides and, ultimately, into individual amino acids (Hadari et al., 
1992). Once amino acids are deaminated, the carbon skeleton can then be used by the 
muscle cell as an energy substrate. Amino acids often affect protein fluxes via negative 
feedback. For example, when the branched-chain amino acid leucine begins to 
accumulate due to use as an energy substrate wanes, its increased binding of leucyl-tRNA 
synthetase activates the downstream transcription factor RAG GTPase (Han et al., 2012), 
which signals via mTORC-1 to inhibit further protein degradation (Han et al., 2012).    
 
Adipose Tissue Development  
 Adipose tissue develops from two different linages of adipocytes, brown and 
white, which are equally prominent within the perirenal-abdominal region during 
proliferative phases in early fetal development. However, the unilocular lipid-rich (white) 
adipocyte progress in greater abundance than the multilocular mitochondria-rich (brown) 
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adipocytes near term and after birth (Clarke et al., 1997; Pope et al., 2014). As adipocytes 
mature, brown adipocyte activation for growth and thermogenesis function is regulated 
by the expression of uncoupling protein 1 (UCP1) (Gemmell et al., 1972), whereas white 
adipocyte activation is regulated by leptin expression (Yuen et al., 2002). Adipose tissue 
accounts for only a small percentage of body weight at birth, but its role perinatal 
thermoregulation is vital. Brown adipose tissue is particularly important for 
thermoregulation during the perinatal period to prevent hypothermia. Heat production by 
brown adipose tissue is facilitated by increased UCP1 abundance in response to 
stimulatory factors such as increased catecholamine, cortisol, and/or prolactin 
concentrations near term (Symonds et al., 2000; Mostyn et al., 2002; Mostyn et al., 
2003). UCP1 expression peaks shortly after birth and then gradually diminishes along 
with the reduction of brown adipose depots, as other thermoregulatory mechanisms such 
as shivering take their place (Clarke et al., 1997; Mostyn et al., 2002). The progressive 
loss of brown adipose tissue coincides with increased abundance of white adipose tissue 
under the skin and around organs (Gemmell et al., 1972; Symonds et al., 1992). The 
expansion of white adipose tissue may occur through hypertrophy or hyperplasia based 
on diet, environment, and metabolic factors. Visceral white adipose tissue predominately 
increases by hypertrophy of existing adipocytes (Wang et al., 2013). However, this is 
often linked to adipose insulin resistance and an increased risk for obesity, cardiovascular 
disease, and metabolic syndrome (Miyazaki and DeFronzo, 2009). Conversely, 
subcutaneous fat depots typically expand by hyperplasia, which is an increase in 
adipocyte number rather than size (McLaughlin et al., 2011). Subcutaneous white adipose 
tissue expansion is inversely associated with the development of insulin resistance. 
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Further research is warranted to determine how prenatal stress impacts white adipose 
tissue expansion postnatal and whether differences in visceral and subcutaneous 
adipocyte expansion is a factor in adipose-driven compensatory growth in IUGR-born 
livestock.  
 
Fatty Acid Mobilization & Utilization for Energy 
 Adipose tissue is a reservoir for energy that the body utilizes in situations of 
negative energy balance. During conditions such as fasting or hypoglycemia, lipids are 
mobilized by the breakdown of stored triglycerides into free fatty acids (FFA), which are 
then released into circulation and utilized by tissues (Lafontan and Langin, 2009). Under 
low-nutrient conditions, increased catecholamine secretion mediates a β adrenergic 
response that stimulates FFA mobilization (Beard et al., 2018). In skeletal muscle, fatty 
acid binding proteins facilitate FFA uptake, which are oxidized upon insulin stimulation 
to provide energy (Pan et al., 1997). However, when FFA accumulate in muscle tissues 
due to being taken up at a greater rate than they are metabolized, a toxic intracellular 
environment is created that impairs skeletal muscle insulin signaling (Ghosh et al., 2007). 
Similar FFA accumulation in pancreatic islets reduces glucose-stimulated insulin 
secretion from β-cells (Sako and Grill, 1990), which further contributes to insulin 
resistance and obesity (Lelliott and Vidal-Puig, 2004).  
 
Bioelectrical Impedance Analysis of Body Composition 
Body condition scoring is the most common method of estimating body 
composition in livestock. However, this method is highly subjective and limited to 
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exterior assessment of fat deposition and muscle mass, which doesn’t account for visceral 
fat depots. Quantitative measurements by bioelectrical impedance analysis (BIA) offer a 
more objective and repeatable method to estimate differences in whole-body protein and 
fat content, allowing the ability to predict the mass of whole or specific muscle groups 
(Berg et al., 1996). This tool is complimentary to body mass index tests in humans and 
has been shown to be an effective non-invasive technique. Bioelectrical impedence 
analysis utilizes resistance and reactance of electrical stimulation through body tissue 
rather than tissue biopsy to estimate whole body composition (Berg et al., 1996; 
Bohuslavek et al., 2002; Avril et al., 2013). More specifically, BIA has been used to 
predict the body composition indicators of fat-free mass (FFM), fat-free soft tissue 
(FFST), nutrient composition, and mass of specific muscle groups in many mammalian 
species (Berg et al., 1996; Bohuslavek et al., 2002; Avril et al., 2013). However, it is 
important to note that BIA is an estimation tool that relies on accurate species and age-
specific prediction equations developed from known measurements determined by 
morphometric analysis.  
 
Skeletal Muscle Glucose Metabolism 
Proper skeletal muscle development and growth is essential in maintaining 
homeostatic glucose concentrations, as skeletal muscle accounts for upward of 60% of 
whole-body glucose utilization, and 85% of insulin-stimulated glucose metabolism 
(Brown, 2014). Glucose is the primary energy substrate for muscle. Its utilization by 
muscle is tightly regulated by insulin, which is secreted in response to elevated blood 
glucose concentrations (Rommel et al., 2001; Limesand et al., 2007a). Insulin signaling 
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activates the canonical Akt/PI3-K pathway, which stimulates the translocation of the 
glucose transporter GLUT4 from the cytosol to the membrane. Once embedded, it creates 
a channel for glucose to enter the muscle cell down its concentration gradient (Bertacca et 
al., 2005) (Limesand et al., 2007a). When blood glucose is elevated, insulin also acts on 
the liver to inhibit hepatic gluconeogenesis (Saltiel and Kahn, 2001), further contributing 
to homeostatic glycemic levels. Once glucose is taken up by skeletal muscle from 
circulation, it is irreversibly converted to glucose 6-phosphate by hexokinase II, which 
prevents its flow back into circulation (da Justa Pinheiro et al., 2010). When energy 
demands are limited, glucose 6-phosphate is stored as glycogen, which provides a local 
source of energy to the skeletal muscle cell (Rozance et al., 2008; Jensen et al., 2011). 
When energy needs increase, glucose 6-phosphate molecules are mobilized from 
glycogen and converted to pyruvate through a cascade of enzymatic reactions known as 
glycolysis. This produces 2 net ATP (Nelson and Cox, 2008). In Type 1 fibers, pyruvate 
is primarily metabolized into acetyl-CoA via decarboxylation or oxaloacetate by 
oxidative phosphorylation, both of which enter the TCA cycle (Nelson and Cox, 2008). 
This produces NADH & FADH2, which are essential electron carriers for oxidative 
phosphorylation by the electron transport chain (Scott et al., 2001; Nelson and Cox, 
2008). Oxidative phosphorylation is the most efficient utilization of glucose, as it 
generates 36 net ATP, but also leaves nothing but the waste products, H2O and CO2. In 
Type IIx fibers, pyruvate is primarily converted to lactate, which produces a much 
smaller amount of ATP but also creates a metabolic substrate that can be released into the 
blood stream for utilization by non-muscle tissue. Normal insulin signaling and oxidative 
capacity in Type I and IIa fibers is imperative for proper function of skeletal muscle 
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glucose metabolism. Glucose deficits can lead to a shift toward less efficient modes of 
skeletal muscle glucose metabolism and increased production of lactate.  
 
The Adrenergic System  
 The adrenergic system consists of a set of signaling pathways that mediate the 
involuntary physiological responses to catecholamines. Epinephrine and norepinephrine 
produced by the adrenal medulla serve as the systemic hormone ligands for the 
adrenergic system by binding 7-transmembrane G-protein coupled adrenoceptors. 
Adrenoceptors exist in nine subtypes that are expressed in various combinations by 
throughout most (if not all) tissues (Ciccarelli et al., 2017). In the fetus, norepinephrine is 
the predominant adrenal catecholamine, and the cortisol surge at parturition stimulates a 
shift to predominant epinephrine production by activating the phosphorylating enzyme 
phenylethanolamine N-methyltransferase (PNMT) (Anthony and Henry, 2015). Ahlquist 
(1948) originally identified two types of adrenoceptors, α and β, that have since been 
further divided into α1A, α1B, α1D, α2A, α2B, α2C, β1, β2, and β3 subtypes. Ligand 
concentrations and binding affinities for individual subtypes determine which 
catecholamine is most likely to activate each adrenoceptor (Anthony and Henry, 2015). 
In response to acute stress, signals from the sympathetic nervous system stimulate 
chromaffin cells within the adrenal medulla to release catecholamines into the blood 
stream (De Diego et al., 2008). This process is initiated by the binding of acetylcholine to 
its receptor, which stimulates the opening of Ca2+ channels on the plasma membrane. The 
resulting Ca2+ influx increases intracellular cAMP and, ultimately, exocytosis of 
catecholamine-filled vesicles (García et al., 2006). Catecholamines then mediate 
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physiological responses including vasodilation and vasoconstriction as well as 
modification of insulin action, glucose and lipid metabolism, and pancreatic islet function 
(William Tank and Lee Wong, 2011).   
 
Adrenergic Regulation of Muscle Growth  
 In skeletal muscle, the most prominent adrenoceptor subtype is β2, but β1 and β3 
subtypes are also expressed. β2 adrenoceptors are typically excitatory and most 
commonly signal via Gαs proteins, activating adenylyl cyclase, which is responsible for 
intercellular cAMP production (Nonogaki, 2000; Yang and Tao, 2019). The 
accumulation of cAMP activates protein kinase A (PKA), which leads to physiological 
responses vital for muscle growth (Figure 1-1). Sustained β2 activation increases lean 
muscle mass by stimulating protein synthesis and limiting protein degradation, resulting 
in a positive protein balance (Beermann, 2002). This is primarily accomplished through 
the activation of Akt and its downstream protein synthesis mediator, mTORC1 (Bodine et 
al., 2001). β2 adrenoceptors also mediate vasodilation of arterioles in skeletal muscle, 
allowing for increased blood flow to supply the necessary nutrients for hypertrophy (Kaur 
et al., 2014). 
 
Adrenergic Regulation of Metabolism  
 The adrenergic system also plays a role metabolic regulation. Adrenoceptors in 
pancreatic islets, skeletal muscle, and adipose tissues mediate changes in the metabolic 
fate of nutritional substrates (Nonogaki, 2000). Within skeletal muscle, acute activation 
of β2 adrenoceptors decreases glucose uptake and increases glycogen breakdown by 
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glycogenolysis (Anthony and Henry, 2015). This is important in hypoglycemic 
conditions, as glucose mobilized by glycogenolysis can be used by the muscle or secreted 
as lactate and taken up by the liver for gluconeogenesis in a process known as the Cori 
Cycle (Rozance et al., 2008). Despite reducing glucose uptake, β2 adrenoceptors 
stimulate skeletal muscle glucose oxidation both in the presence and in the absence of 
insulin (Cadaret et al., 2017). Signaling through β1 and β3 adrenoceptors in adipose tissue 
decreases glucose uptake in adipocytes and induces lipolysis, thus mobilizing free fatty 
acids that can be utilized by skeletal muscle and other tissues for β-oxidation (Beard et 
al., 2018; Yang and Tao, 2019). In the liver, activation of β1 and β2 receptors stimulate 
glycogenolysis and increase glucose production, fatty acid breakdown, and ketone body 
formation (Anthony and Henry, 2015). These metabolic shifts collectively result in 
increased blood glucose, ketone body, free fatty acid, lactate, and glycerol concentrations. 
This helps re-appropriate the supply of energy substrates to vital organs at the expense 
muscle and other peripheral tissues (Nonogaki, 2000).  
In pancreatic islet β cells, α and β adrenoceptors play differing roles in 
maintaining glucose homeostasis. Under fasting conditions, elevated catecholamines 
inhibit insulin secretion  predominantly via α2 adrenoceptors, which prevent adenylyl 
cyclase-induced exocytosis of insulin vesicles (Chen et al., 2017). In response to low 
blood glucose, β2 adrenoceptors located on pancreatic islet α cells stimulate glucagon 
secretion to increase blood glucose through glycogenolysis, facilitating the return of 
homeostatic blood glucose levels (Limesand et al., 2006).  
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The Inflammatory System  
Inflammatory Signaling 
Inflammation is among the first defense mechanisms for the immune system but 
is also an important regulator of metabolism and other physiological functions. 
Inflammatory mediators initiate responses through a series of chemical intracellular 
signaling pathways (Chen et al., 2018). Toll-like receptors (TLR) on the surface of cells 
are activated by pathogen-associated molecular patterns (PAMPS) or other factors and 
modulate intracellular signaling necessary for phagocytosis and other responses 
associated with inflammation. Cytokines, which are small signaling proteins secreted by 
numerous cell and tissue types, are primary contributors to the inflammatory response by 
binding to specific receptors, which activate intracellular signaling pathways for 
inflammation (Chen et al., 2018). Key components of many inflammatory cytokine 
pathways include Nuclear Factor κ-B (NFκB), mitogen-activated protein kinase (MAPK), 
and Janus kinase (Jak)-signal transducer and activator of transcription (STAT) (Rawlings 
et al., 2004; Bollrath and Greten, 2009).  
 Nuclear Factor κ-B is a major hub of multiple inflammatory signaling pathways, 
including those initiated by TLR4, TLR2, and TLR6 as well as the cytokines interlukin-
1β (IL-β), IL-6, and TNFα (Chen et al., 2018). Downstream proinflammatory mediator, 
NFκB, can be activated through two separate IκB kinase (IKK) complex subunits that 
respond to distinct stimulants and act on different regulatory complexes (Bollrath and 
Greten, 2009). The IKK complex consists of two kinase subunits, IKKα and IKKβ, 
coupled with a regulatory subunit IKKγ (Lawrence, 2009). The canonical NFκB pathway 
is preferentially activated by TNFα, IL-β, and TLR and is mediated by IKKβ and IKKγ. 
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The NFκB pathway ultimately increases cytokines and other inflammatory factors by 
activating RelA/p50 dimerization (Bollrath and Greten, 2009; Lawrence, 2009). TNFα-
induced IKK activation is predominantly facilitated by TNF receptor 1 (TNFR1) 
signaling complex but can also be stimulated by a second receptor, TNFR2, in some 
tissues. Activation of TNFR1 stimulates the recruitment of adaptor proteins such as 
tumor necrosis factor receptor-associated factors (TRAF) and Tumor Necrosis Factor-
Associated Death Domain (TRADD), which are necessary for the IKK phosphorylation 
that leads to canonical NFκB activation. The non-canonical pathway for NFκB activation 
is typically stimulated by other members of the TNF-superfamily such as TWEAK, 
lymphotoxin β (LB), or β-cell Activating Factor (BAFF) (Bollrath and Greten, 2009). 
The non-canonical NFκB pathway is mediated by the IKKα subunit and increases gene 
expression associated with long-term cell survival by activating RelB/p52 dimerization 
(Lawrence, 2009). Lipopolysaccharides can also activate the non-canonical NFκB 
pathway through TLR4 (Chow et al., 1999; Faure et al., 2001). This pathway involves the 
activation of mitogen-activated protein kinases, which are responsible for subsequent 
increases in cytokine production (Cadaret et al., 2019b). 
 
Inflammatory Regulation of Muscle Growth 
 Inflammatory factors including cytokine signaling contribute to the development, 
growth, and regeneration of skeletal muscle, but prolonged exposure to elevated 
cytokines disrupts these physiological processes. Two prominent inflammatory cytokines 
are secreted by skeletal muscle fibers and resident macrophages. Myoblast exposure to 
both TNFα and IL-6 reduce skeletal muscle growth, myoblast function, and protein 
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synthesis over time (Thoma and Lightfoot, 2018; Cadaret et al., 2019c; Posont, 2019). 
During fetal development, these cytokines regulate myogenesis by increasing 
proliferation of myoblasts (Posont et al., 2018). However, prolonged exposure of TNFα  
and IL-6, due to poor intrauterine conditions can lead to intrinsic deficits in myoblast 
function which persist after birth (Yates et al., 2014; Soto et al., 2017; Cadaret et al., 
2019b). Elevated IL-6 and TNFα-induced NFκB activation disrupts terminal myoblast 
differentiation and inhibits protein synthesis (Langen et al., 2001). This is due to NFκB 
activation reducing expression for the differentiation factors MyoD and myogenin and 
the structural protein desmin (Langen et al., 2001; Posont et al., 2018). Myoblast 
dysfunction prenatal in turn reduces fetal muscle mass and further hypertrophic growth 
capacity (Cadaret et al., 2019b). Postnatal, acute increases in cytokine signaling via 
STAT3 pathways induce quiescent satellite cells to proliferate in order to facilitate 
hypertrophic muscle growth (Zhang et al., 2013). However, chronic activation of these 
regulatory pathways leads to myoblast dysfunction, increased protein degradation, 
muscle wasting, and ultimately reduced skeletal muscle mass (Yates et al., 2014; Brown 
and Hay Jr, 2016; Posont et al., 2018). This is particularly evident in fetuses exposed to 
chronically-elevated cytokines during peak myogenesis, which leads to intrinsic deficits 
in inflammatory regulation of postnatal muscle growth. This appears to be a result of 
adaptions in myoblast cytokine sensitivity, which is evidenced by reduced myoblast 
responsiveness to TNFα and IL-6 during proliferation and differentiation (Yates et al., 
2016; Posont et al., 2018).   
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Inflammatory Regulation of Metabolism  
 The inflammatory system plays a role in metabolic regulation and substrate 
utilization via both acute and chronic changes. During normal physiological conditions, 
NFκB activation initiates transcription of genes for glycolysis, thus shifting glucose 
metabolism to a less efficient route of energy production (Tornatore et al., 2012). In 
skeletal muscle, TNFα and IL-6 act through both the canonical and non-canonical NFκB 
pathways to regulate basal and insulin-stimulated glucose metabolism. One mechanism 
for regulating energy utilization by skeletal muscle is inhibition of insulin-stimulated 
glucose uptake (del Aguila et al., 1999). Elevated inflammatory cytokines block insulin-
stimulated Akt phosphorylation, which prevents the translocation of GLUT4 to the 
plasma membrane of the muscle cell (Figure 1-3) (Lorenzo et al., 2008) (Pirola et al., 
2004). However, acute TNFα and IL-6 exposure in some conditions can also increase 
glucose uptake independently of insulin through the activation of the non-canonical 
NFkΒ pathway (Carey et al., 2006; Glund et al., 2007). In addition, cytokine exposure 
following acute stress is also effective in directly increasing skeletal muscle glucose 
oxidation in the absence of insulin and independently of glucose uptake (Cadaret et al., 
2017).  
In pancreatic islets, IL-6 signaling via JAK/STAT3 supports homeostatic glucose 
metabolism by promoting development of pancreatic islet microvasculature (Kostromina 
et al., 2010). When activated, STAT3 promotes the expression of Vascular Endothelial 
Growth Factor A (VEGF-A), which is critical for the proper development of 
microvasculature in the pancreatic islet cells (Kostromina et al., 2010).  Poor islet 
microvasculature development can reduce insulin secretion and result in glucose 
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intolerance (Lee and Hennighausen, 2005; Kostromina et al., 2013). This form of glucose 
intolerance is a primary contributor to Type II diabetes and obesity (Cui et al., 2004). The 
temporal differences in TNFα and IL-6 action suggests that inflammatory regulation of 
metabolism relies on the duration of cytokine exposure. Chronic exposure during fetal 
development impairs postnatal regulation of glucose metabolism which is evidenced by 
reduced TNFα-stimulated skeletal muscle glucose oxidation (Cadaret et al., 2018).  
  
Adaptive Programming of Adrenergic & Inflammatory Regulation in IUGR  
 The consequences of IUGR on growth and metabolism stem in large part from 
adaptive programming mechanisms that alter inflammatory and adrenergic action. When 
fetal stress pathways are upregulated due to reduced glucose and oxygen availability, 
nutrient-sparing adrenergic adaptions disrupt muscle development, hypertrophic growth, 
and oxidative capacity (Yates et al., 2014; Yates et al., 2016). In addition, fetal pancreatic 
islet development is diminished, resulting in impaired insulin secretion in IUGR fetuses 
and offspring (Limesand et al., 2007a; Rozance et al., 2009; Limesand and Rozance, 
2017b). These pathologies are in part due to the chronic exposure of fetal tissues to 
increased catecholamines and cytokines, which causes developmental changes in the 
nature of their signaling pathways and thus programs life-long dysfunction  (Figure 1-2) 
(Yates et al., 2011a; Chen et al., 2017; Limesand and Rozance, 2017b; Posont et al., 
2018). As IUGR offspring mature, it is important to understand the underlying 
mechanisms associated with these pathologies and when and how they can be mediated. 
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Improving Adrenergic Pathologies of IUGR with β-agonists 
 Thorough research has shown the effects of stimulating adrenergic activity with β 
adrenergic agonists on muscle growth and metabolic efficiency in multiple species of 
livestock. In fact, β agonists are utilized as feed additives in 70% to 90% of all cattle in 
US feedlots (Johnson et al., 2013; Johnson et al., 2014). The β2 agonist clenbuterol HCl is 
particularly effective in enhancing muscle growth through increased protein synthesis and 
attenuation of muscle atrophy (Maclennan and Edwards, 1989; Hinkle et al., 2002). In 
addition, clenbuterol improves body composition by reducing adipose deposition (Ricks 
et al., 1984; Miller et al., 1988). The mechanisms by which clenbuterol acts are not fully 
elucidated, but it is clear that clenbuterol binds to β2 adrenoceptors in skeletal muscle 
(Hinkle et al., 2002). The effects of clenbuterol are typically longer lasting than other β-
agonists, making clenbuterol an ideal means for mediating chronically altered 
mechanisms such as those present in IUGR tissues although currently prohibited for use 
in livestock. Improvements in lean muscle mass and metabolic efficiency measured by 
increased carcass merit and feed-to-gain ratios have been achieved with β-agonists in 
uncompromised livestock, and we will seek to determine the effects of β-agonist 
supplementation on poor gain and altered body compositions in IUGR-born animals. 
 
Meditating Enhanced Inflammatory Sensitivity in IUGR  
The use of nonsteroidal anti-inflammatory drugs (NSAID) in the treatment of 
chronic inflammatory disorders is a common means to reduce cytokine action on tissues 
that contribute to systemic inflammation (Enthoven et al., 2016). However, prolonged use 
of these drugs and chronic suppression of inflammatory pathways can have severe 
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consequences on the regulatory properties of inflammation on muscle growth and 
metabolism. Inflammatory pathways provide key regulatory signals that when chronically 
impaired have the potential to disrupt the balance of protein cycling and energy substrate 
utilization. In addition, the chronic usage of NSAID have been correlated with the 
increased risk of gastrointestinal bleeding, renal disease, and cardiovascular disease 
(Bauer et al., 1996; Gooch et al., 2007; Verhaegh et al., 2016). Thus, alternatives to 
NSAID such as curcumin, a nutraceutical, are warranted. Curcumin is the bioactive 
polyphenol of the root of the Turmeric (Curcuma longa) plant. Cell culture studies 
indicate that curcumin has antioxidant and anti-inflammatory properties and is 
particularity effective in reducing TNFα/TNFR1-induced NFκΒ activation (Leclercq et 
al., 2004; Gonzales and Orlando, 2008; Sadeghi et al., 2018), which could reduce the 
impact of enhanced inflammatory pathways on skeletal muscle growth and metabolism in 
IUGR offspring. 
 
Conclusion 
Our recent studies have connected fetal adaptions in adrenergic and inflammatory 
signaling pathways to reductions in neonatal growth and metabolic performance in 
IUGR-born offspring (Cadaret et al., 2019c; Posont, 2019; Yates et al., 2019a). 
Understanding how pathologies lead to these adaptions and progressively worsen 
throughout early life will help identify underlying mechanisms that could be targeted to 
improve later life health deficits. As such, the objective of the following studies were 
directed at determining if fetal and neonatal IUGR growth and metabolic deficits worsen 
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as these offspring enter the juvenile stage and whether these adaptive programming 
mechanisms can be treated through the use of adrenergic or inflammatory modifiers.  
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Figure 1-1. The modulation of intercellular cAMP production and action in response to β 
adrenoreceptor binding.  
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Figure 1-3. Illustration of the mechanisms involved in insulin-stimulated glucose uptake 
for skeletal muscle, which can be inhibited by elevated cytokine exposure.  
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Chapter 2 
Deficits in growth, muscle mass, and body composition caused by placental 
insufficiency-induced intrauterine growth restriction persisted in lambs at 60 d of 
age but were improved by daily supplementation of clenbuterol or curcumin.1 
 
1A version of this chapter containing minimal modification has been accepted for 
publication by Translational Animal Science. 
 
ABSTRACT  
 Placental insufficiency consistently induces intrauterine growth restriction 
(IUGR), and the consequences follow the individual through postnatal life. In meat 
animals, IUGR causes reduced muscle mass and asymmetric growth that favors of fat 
deposition. The resulting body composition is detrimental to carcass value at harvest. We 
hypothesized that IUGR fetal adaptions would continue to negatively impact postnatal 
growth and body composition of juvenile-aged lambs but that adrenergic and 
inflammatory modifiers would improve growth deficits at this age. Thus, the objective of 
this study was to assess the impact of IUGR in juvenile lambs to determine whether 
diminished growth and body composition could be recovered by daily postnatal treatment 
with clenbuterol or curcumin. IUGR lambs were produced by maternal hyperthermia-
induced placental insufficiency and growth metrics were assessed over the 1st 60 d of age. 
At all assessed ages, bodyweight (BW) and average daily gain were diminished (P < 
0.05) and crown-to-rump tended to be reduced (P = 0.07) in unsupplemented IUGR 
lambs compared to controls, but IUGR lambs treated with clenbuterol or curcumin did 
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not differ from controls. Crown circumference, body girth, and crown circumference-to-
body girth ratios were greater (P < 0.05) in curcumin-supplemented IUGR lambs than 
controls at birth, but crown circumference-to-body girth ratios were reduced (P < 0.05) in 
curcumin-supplemented IUGR lambs by 60 d. At necropsy, brain-to-BW ratio, hindlimb, 
heart, and flexor digitorum superficialis (FDS) muscle mass tended to be reduced (P ≤ 
0.09) in IUGR lambs compared to controls, but the FDS muscle mass did not differ 
between curcumin-supplemented IUGR lambs and controls. Lung and kidney mass, lung-
to-BW ratio, and kidney-to-BW ratio were also diminished (P < 0.05) in IUGR lambs 
compared to controls. Kidney mass was further diminished (P < 0.05) in clenbuterol-
supplemented and curcumin-supplemented IUGR lambs compared to unsupplemented 
IUGR lambs, but lung mass and lung-to-BW ratio in clenbuterol-supplemented IUGR 
lambs did not differ from controls. Regardless of experimental group, females exhibited 
larger (P < 0.05) hindlimb, heart, kidney, and liver masses compared to males, but males 
had larger (P < 0.05) lung-to-BW and brain-to-BW ratios. Group x age interactions were 
observed (P < 0.05) for BIA estimated body composition, nutrient composition, and 
muscle composition, which were not different among experimental groups at 30 d of age. 
Fat-free mass (FFM) and fat-free soft tissue (FFST) were also not different at 60 d of age, 
but estimated mass of several muscle groups were reduced (P < 0.05) in IUGR lambs 
compared to controls, clenbuterol-supplemented IUGR lambs, and curcumin-
supplemented IUGR lambs. At necropsy, FFM, FFST, and mass of muscle groups were 
all less (P < 0.05) in unsupplemented IUGR lambs than in controls, clenbuterol-
supplemented IUGR lambs, and curcumin-supplemented IUGR lambs. Estimated crude 
fat and nutrient composition values for moisture, protein, fat, and lean content were less 
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(P < 0.05) in unsupplemented but not clenbuterol-supplemented or curcumin-
supplemented IUGR lambs than controls. Actual loin eye area (REA) and loin protein 
content measured at necropsy were less (P < 0.05) in unsupplemented IUGR lambs but 
greater (P < 0.05) in clenbuterol-supplemented IUGR lambs compared to controls and 
curcumin-supplemented IUGR lambs. Loin fat content, fat-to-protein ratio, and caloric 
content were all greater (P < 0.05) in unsupplemented IUGR lambs compared to controls, 
clenbuterol-supplemented IUGR lambs, and curcumin-supplemented IUGR lambs. From 
these findings, we conclude that IUGR reduces postnatal growth performance and 
decreases body composition quality through 2 mo of age, but postnatal treatment with 
clenbuterol or curcumin was effective in recovering several aspects of poor growth, 
which allowed for improved body composition in IUGR lambs.  
 
INTRODUCTION 
 Low birthweight in livestock results from stress-induced intrauterine growth 
restriction (IUGR) of the fetus (Yates et al., 2018a). These animals exhibit diminished 
muscle mass at term that persists in the neonatal stage (Brown and Hay Jr, 2016; Cadaret 
et al., 2019b). When coupled with metabolic dysfunction, poor muscle growth leads to 
asymmetric body composition and decreased weight gain (Cadaret et al., 2019c). 
Ultimately, low birthweight pathologies result in poor carcass yield and merit at harvest 
(Greenwood et al., 1998), resulting in price discounts and reduced profitability for 
producers (Boleman et al., 1998). Poor performance and compromised wellbeing 
associated with low birthweight make it necessary to develop postnatal treatment 
strategies aimed at improving outcomes of IUGR. In this study, we examined the 
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potential benefits of daily supplementation of two bioactive compounds aimed at 
targeting adrenergic and inflammatory adaptations that we previously observed in IUGR 
muscle tissues (Posont et al., 2018; Yates et al., 2018a). First, adrenergic activity was 
manipulated by daily injections of clenbuterol, a pharmaceutical β2 adrenergic agonist 
that is a well-characterized stimulant of muscle growth and efficiency in livestock 
(Beermann, 2002). Second, inflammatory activity was manipulated by oral administration 
of curcumin, a nutraceutical extract of turmeric root that elicits anti-inflammatory 
properties by disrupting NFκB-mediated inflammatory pathways (Leclercq et al., 2004; 
Cho et al., 2007). We previously reported that IUGR diminished muscle growth and 
altered body composition at the neonatal stage (Cadaret et al., 2019c). In this study, we 
hypothesized that growth deficits would persist at the juvenile stage, manifesting in poor 
body composition and diminished carcass merit indicators. We also postulated that daily 
postnatal supplementation of clenbuterol and curcumin would at least partially recover 
growth and body symmetry in IUGR-born lambs at 60 d of age. The objective of this 
study was to test this hypothesis by determining the extent to which IUGR fetal adaptions 
impair growth capacity over the first 60 d of age. We also sought to determine whether 
clenbuterol or curcumin could improve IUGR-induced deficits in lean tissue growth to 
provide a more desirable body composition. 
 
MATERIALS & METHODS  
Animals and Experimental Design  
These studies were approved by the Institutional Animal Care and Use Committee 
at the University of Nebraska-Lincoln, which is accredited by AAALAC International. 
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Placental insufficiency-induced IUGR lambs were produced from Polypay ewes as 
previously described (Cadaret et al., 2019). Briefly, timed-mated ewes (18 to 24 mo of 
age at breeding) were exposed to elevated ambient temperatures of 40°C with a relative 
humidity of 35% during peak placental development from the 40th to 95th d of gestational 
age. Ewes were returned to thermoneutral temperatures (25°C) alongside their pair-fed 
control counterparts following the 55-d exposure, and all ewes were allowed to lamb 
naturally. Nutritional management, housing, and husbandry for all ewes were practiced as 
previously described (Macko et al., 2016b). Following parturition, lambs were weaned at 
12 h of age and hand-reared until 60 d of age. After being fed a minimum of 200 ml 
colostrum (pooled from multiple ewes) within the first 24 h, lambs were raised on milk 
replacer (Land O’Lakes Inc., Arden Hills, MN) for the first 30 d. Lambs were hand fed 
every four hours until trained to eat from stationary bottle hangers, typically within 5 d of 
birth. Milk bottles were replaced twice daily. Lambs were then transitioned to the ad 
libitum grain diet in Table 2-1 beginning at 30 d of age, and milk replacer was 
discontinued at 45 d of age. IUGR lambs were randomly assigned at birth to receive one 
of the three daily treatments outlined in Table 2-2 (IUGR: n=6; IUGR+Clenbuterol: n=7; 
IUGR+Curcumin: n=5). Control lambs (n=11) received both treatment placebos.  
 
Growth Metrics  
Crown circumference, front cannon bone length, body girth just behind the 
shoulder blades, and crown-rump length were measured at birth and weekly thereafter for 
a total of 8 weeks. Lamb bodyweights (BW) and feed intake were recorded daily. Lambs 
were euthanized by double barbiturate overdose and necropsied at 60 d of age. Brain, 
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heart, lungs, kidneys, liver, and flexor digitorum superficialis muscles were weighed. 
Following necropsy, lamb carcasses were chilled for a minimum of 24 h and then split 
between the 12th and 13th rib where ribeye area (REA) was measured utilizing Iowa State 
University’s Plastic Grid for Quick Measurement. 
 
In vivo Body Composition Estimations  
Bioelectrical impedance analysis was performed at 30 and 60 d of age in the live 
animal to estimate body composition. It was also performed on the longissimus dorsi 
muscle at necropsy. A four-terminal Quantum V (RJL Systems, Detroit, MI) was used to 
measure reactance (Xc), resistance (Rs), and phase angle (PA). Each BIA utilized two 
sets of equally spaced electrode terminals to transmit an electrical current across the 
tissues. Electrodes were connected to aluminum 20G MONOJECT needles (Covidien, 
Mansfield, MA) placed subcutaneous in live animals and intramuscular in the 
longissimus dorsi. The outer electrodes were placed 2.5 cm behind the point of the 
scapula and 5 cm in front of the hip bone, and the inner electrodes were placed 2.5 cm 
inside of these. Both sets were placed dorsally 1 cm to the right of the midline. 
Measurements were recorded for 30 sec, with one measurement every 5 sec, resulting in 
six total measurements that were averaged. Also at necropsy, the contralateral 
longissimus dorsi muscle was removed, frozen, and sent to Midwest Laboratories 
(Omaha, NE) for proximate analysis to determine muscle moisture, protein, fat, ash, 
carbohydrates, and caloric concentrations.  
Ultrasonic measurements of the loin were performed at 60 d of age on a subset of 
lambs comprised of the control group for this study. Lambs were tightly sheared over the 
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12th and 13th ribs from the midline to the lower right flank of the animal. An IBEX PRO 
(E.I. Medical Imaging, Loveland, CO) ultrasound machine with a L6.2 12-cm linear 
transducer was used to measure REA, ribeye depth, and back fat thickness between the 
12th and 13th rib. The transducer was placed at a 45° angle toward the head of the animal 
between the 12th and 13th rib following heavy application of vegetable oil as a couplant. 
REA, ribeye depth, and back fat thickness were then measured from a frozen image 
utilizing the caliper tracing mode.  
 
Statistical Analysis  
 Data were analyzed using SAS 9.4 (SAS Institute, Cary, NC). Necropsy and 
ultrasound data were analyzed for differences among experimental groups by ANOVA 
using the mixed procedure, and Fisher’s LSD was used for mean separation. The main 
effect of sex was also examined, but interacting effects between group and sex were not 
included in the model due to insufficient power. Bodyweights, growth metrics, and 
estimated body composition data were likewise analyzed using the mixed procedure, with 
day as the repeated measure. For bioelectrical impedance data, readings over the 30-s 
period were averaged and the mean was used for the equations. Spearman correlation 
coefficients for ultrasound estimates and actual REA were determined with the 
correlation procedure of SAS. Lamb was considered the experimental unit for all outputs. 
Data are presented as means ± standard error. Significant differences were declared at α ≤ 
0.05 and tendencies at α ≤ 0.10. 
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RESULTS  
Growth Metrics 
An experimental group x age interaction was observed (P < 0.05) for crown 
circumference/abdominal girth but not for BW, average daily gain (ADG), crown 
circumference, body girth, crown-rump length, or cannon bone length. Average BW was 
reduced (P < 0.05) for IUGR lambs compared to all other groups, regardless of age 
(Figure 2-1A). ADG was reduced (P ≤ 0.05) for unsupplemented, clenbuterol-
supplemented, and curcumin-supplemented IUGR lambs compared to controls, whether 
determined at 30 d or 60 d (Figure 2-1B). ADG between birth and the 30th d of age 
tended to be greater (P = 0.10) than between the 30th and 60th d for all lambs, regardless 
of experimental group (Figure 2-1C). Crown circumference and abdominal girth were 
greater (P ≤ 0.05) in curcumin-supplemented IUGR lambs compared to all other groups, 
regardless of age. Crown-rump length tended to be diminished (P = 0.07) in IUGR lambs 
compared to all other groups, regardless of age. Cannon bone length did not differ among 
experimental groups. At birth, crown circumference/abdominal girth was greater (P ≤ 
0.05) for IUGR and curcumin-supplemented IUGR lambs than for controls and 
clenbuterol-supplemented IUGR lambs. After 8 weeks, however, crown 
circumference/abdominal girth was less (P ≤ 0.05) for curcumin-supplemented IUGR 
lambs than controls but not IUGR and clenbuterol-supplemented IUGR lambs. BW, 
ADG, and growth metrics did not differ between sexes. 
At necropsy, hindlimb mass for IUGR lambs tended to be lighter (P = 0.09) than 
controls, but hindlimb mass for curcumin-supplemented and clenbuterol-supplemented 
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IUGR lambs did not differ from controls (Table 2-3). Female hindlimbs were heavier (P 
≤ 0.05) than male hindlimbs (Table 2-4). Hindlimb mass/BW did not differ among 
experimental groups or between sexes. The flexor digitorum superficialis muscle mass 
tended to be lighter (P = 0.06) for IUGR lambs than controls or curcumin-supplemented 
IUGR lambs, but its mass in clenbuterol-supplemented and curcumin-supplemented 
IUGR lambs did not differ from controls. Flexor digitorum superficialis muscle mass/BW 
did not differ among experimental groups or between sexes. Heart weights tended to be 
smaller (P = 0.09) in unsupplemented, curcumin-supplemented, and clenbuterol-
supplemented IUGR lambs than in controls, and were heavier (P ≤ 0.05) in females than 
males. Heart weight/BW did not differ among experimental groups or between sexes. 
Lung weight and lung weight/BW ratio were lower (P ≤ 0.05) for IUGR lambs than for 
controls but did not differ among clenbuterol-supplemented IUGR lambs, curcumin-
supplemented IUGR lambs, and controls. Lung weight/BW was greater (P ≤ 0.05) in 
males than females. Liver weight and liver weight/BW did not differ among experimental 
groups, but liver weight tended to be higher (P = 0.06) in females than males. Kidney 
weight was lighter (P ≤ 0.05) for IUGR lambs than for controls and was lighter (P ≤ 
0.05) for curcumin-supplemented and clenbuterol-supplemented IUGR lambs than for 
controls or unsupplemented IUGR lambs. Kidney weight was higher (P ≤ 0.05) in 
females than males. Kidney weight/BW ratio did not differ between controls and 
unsupplemented IUGR lambs but was lower (P ≤ 0.05) for curcumin-supplemented and 
clenbuterol-supplemented IUGR lambs than for controls or unsupplemented IUGR 
lambs. Brain weight was not different among experimental groups or between sexes. 
Brain weight/BW tended to be lower (P = 0.07) for unsupplemented, curcumin-
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supplemented, and clenbuterol-supplemented IUGR lambs than for control lambs and 
was higher (P ≤ 0.05) in males than females. Loin eye area was smaller (P ≤ 0.05) in 
IUGR lambs than controls, larger (P ≤ 0.05) in clenbuterol-supplemented IUGR lambs 
than controls, and did not differ between curcumin-supplemented IUGR lambs and 
controls. Loin eye area was also larger (P ≤ 0.05) in females than in males. 
  
In vivo Body Composition Estimations  
 Experimental group x age interactions were observed (P ≤ 0.05) for all BIA 
estimates. No differences in any body composition, nutrient composition, or muscle 
composition estimated were observed among experimental groups at 30 d of age (Table 
2-5). At 60 d of age, however, 1 of the 3 FFM equations (FFM1) indicated that FFM was 
lower (P < 0.05) in IUGR lambs but greater (P ≤ 0.05) in curcumin-supplemented IUGR 
lambs compared to controls. This equation also indicated that FFM for clenbuterol-
supplemented lambs did not differ from controls or curcumin-supplemented IUGR lambs 
but was still greater (P ≤ 0.05) than IUGR lambs. The remaining FFM equations and all 
FFST equations did not indicate a difference among experimental groups at 60 d of age. 
The estimated sum of the leg, sirloin, rack, shoulder, neck, riblets, shank, and lean trim 
mass (SUM) as well as the sum of the leg, sirloin, loin, rack, and shoulder mass (LSRLS) 
and the sum of the leg, sirloin, and loin mass (LSL) were all less (P < 0.05) in IUGR 
lambs than in controls or curcumin-supplemented IUGR lambs at 60 d of age. In 
clenbuterol-supplemented IUGR lambs, these estimates were intermediate and did not 
differ from any of the other group. Nutrient composition estimations indicated no 
difference in moisture, lean mass, or protein content at 60 d of age. However, estimated 
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fat content was less (P ≤ 0.05) for IUGR lambs than for controls or curcumin-
supplemented IUGR lambs. Estimated fat content for clenbuterol-supplemented IUGR 
lambs was again intermediate and did not differ from any of the other experimental 
groups. Crude fat content (CF) indicated by the CF3 equation was likewise reduced (P < 
0.05) in IUGR lambs compared to control and curcumin-supplemented IUGR lambs but 
not clenbuterol-supplemented IUGR lambs.   
At necropsy, all equations indicated that FFM and FFST were reduced (P ≤ 0.05) 
in IUGR lambs compared to controls and curcumin-supplemented IUGR lambs, and 2 of 
3 equations for each parameter indicated that FFM and FFST were also reduced (P ≤ 
0.05) in IUGR lambs compared to clenbuterol-supplemented IUGR lambs. The remaining 
equations indicated that FFM and FFST were lower (P ≤ 0.05) in clenbuterol-
supplemented IUGR lambs than controls at necropsy. Estimated SUM and LSL at 
necropsy were less (P ≤ 0.05) for IUGR lambs than for controls or curcumin-
supplemented IUGR lambs but not different from clenbuterol-supplemented IUGR 
lambs. Estimated LSLRS at necropsy was less (P ≤ 0.05) for IUGR lambs than controls 
but did not differ from curcumin-supplemented or clenbuterol-supplemented IUGR 
lambs. All equations indicated that CF was reduced (P ≤ 0.05) in IUGR lambs compared 
to controls, and 2 of 3 equations indicated that CF was also less (P ≤ 0.05) than in 
clenbuterol-supplemented IUGR lambs. The remaining equation indicated that CF in 
IUGR lambs did not differ from clenbuterol-supplemented IUGR lambs but was less (P ≤ 
0.05) than in curcumin-supplemented IUGR lambs. Nutrient composition estimations at 
necropsy indicated diminished (P ≤ 0.05) moisture, protein, fat, and lean contents for 
IUGR lambs compared to all other groups. BIA estimated fat-to-protein ratios were 
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greater (P ≤ 0.05) in IUGR lambs than controls and clenbuterol-supplemented IUGR but 
did not differ from curcumin-supplemented IUGR lambs. Proximate analysis of the 
contralateral loin muscle collected at necropsy showed no differences among 
experimental groups or between sexes for moisture, ash, and carbohydrate content but 
revealed less (P ≤ 0.05) protein content for IUGR lambs compared to controls and greater 
(P ≤ 0.05) protein content for clenbuterol-supplemented IUGR lambs compared to 
controls. Loins from males tended to have a higher (P = 0.08) protein content than 
females. Loin fat content was increased (P ≤ 0.05) in IUGR lambs compared to controls 
but was not different among clenbuterol-supplemented IUGR lambs, curcumin-
supplemented IUGR lambs, and controls. Loin fat content also did not differ between 
sexes. Loin fat-to-protein content was higher (P ≤ 0.05) in IUGR lambs than in controls 
and in males compared to females but not different among clenbuterol-supplemented 
IUGR lambs, curcumin-supplemented IUGR lambs, and controls. Loin caloric content 
was higher (P ≤ 0.05) in IUGR lambs than in controls but not different among 
clenbuterol-supplemented IUGR lambs, curcumin-supplemented IUGR lambs, and 
controls.  
Correlations between ultrasound estimates of loin eye area, loin eye depth, and 
back fat thickness and actual loin eye measurements indicated that ultrasound-estimated 
loin eye depth was most strongly correlated to actual loin eye area with a correlation 
coefficient of 0.74 (P ≤ 0.05). Ultrasound-estimated back fat thickness had a correlation 
coefficient with actual loin eye area of 0.58 (P = 0.16), and ultrasound-estimated loin eye 
area had a correlation coefficient with actual loin eye area of 0.48 (P = 0.26).  
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DISCUSSION  
In this study, we found that the repercussions of IUGR on postnatal growth and 
body composition were evident in juvenile-aged lambs and paralleled deficits observed at 
younger ages. We also found that daily postnatal treatment with injectable clenbuterol or 
oral curcumin recovered some aspects of diminished postnatal growth and improved 
body composition characteristics by 60 d of age. Specifically, juvenile lambs that were 
born IUGR exhibited morphometric measurements and lean tissue mass parameters that 
were consistent with asymmetrical growth patterns. This phenotype was compounded by 
decreased feed efficiency and rates of gain that coincided with greater fat-to-muscle 
ratios and poorer carcass merit indicators at necropsy. Postnatal supplementation of 
clenbuterol or curcumin recovered indicators of lean tissue mass in IUGR-born lambs, 
thus improving a major factor contributing to the hallmark asymmetric fat-to-protein 
ratios. Clenbuterol supplementation even improved estimated muscle mass beyond that of 
lambs that were not IUGR at birth. Together these finding show that the impact of IUGR 
persists through the juvenile stage but that postnatal supplementation of curcumin or 
clenbuterol can improve and even enhance soft tissue growth and body composition.  
Impaired capacity for growth was present in juvenile-aged IUGR offspring, much 
like we had previously observed in the fetus (Yates et al., 2016) and neonatal offspring 
(Cadaret et al., 2019c; Posont, 2019). However, several of the diminished growth 
indicators were improved by daily administration of the injectable β2 adrenergic agonist 
clenbuterol or the oral anti-inflammatory nutraceutical curcumin to IUGR-born lambs 
over the 1st 60 d of life. Bodyweights and crown-rump lengths, which are metrics of total 
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body growth, were diminished in IUGR lambs at birth. This was expected based on our 
previous findings in IUGR lambs (Cadaret et al., 2019c) However, IUGR-born lambs 
gained weight less rapidly after birth and both bodyweights and crown-rump lengths 
continued to lag behind controls at 1 and 2 mo of age. This suggests that adipose-driven 
catch-up growth had not occurred over this timeframe, and thus juvenile growth patterns 
mirrored the diminished fetal and neonatal growth patterns observed in previous studies 
by us and others (De Blasio et al., 2007; Cadaret et al., 2019c). However, in a recent 
study using the same model of maternal hyperthermia, we found that IUGR lambs were 
20% lighter than their control counterparts at 30 d of age (Cadaret et al., 2019). Here, we 
found that IUGR lambs were only 12% lighter at 60 d of age. We believe this to show 
that as IUGR offspring progress from the neonatal stage to the juvenile stage, the 
discrepancy in their growth rates may dwindle somewhat. Additionally, the slower rates 
of gain for all lambs in the 2nd mo of age compared to the 1st mo suggests less opportunity 
for growth as the animal ages, which would be consistent with previous findings 
(Thiruvenkadan et al., 2011). For IUGR offspring, this could mean less opportunity to 
recover diminished growth.  
The impact of placental insufficiency-induced IUGR was not proportional among 
all morphometric parameters measured in this study. Cannon bone length, for example, 
was not diminished in IUGR lambs at birth or at the neonatal or juvenile stages. This 
indicates that the skeletal structure is protected from growth restriction similar to the way 
that growth of brain, heart, and other vital organs is spared. When these tissues are spared 
at the expense of muscle, fat, and other soft tissues, the result is an asymmetrical pattern 
of growth and body composition that is hallmark to the IUGR fetus (Yates et al., 2014; 
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Posont et al., 2018) and neonate (Cadaret et al., 2019c; Posont, 2019; Yates et al., 2019a). 
Additionally, the higher degree of bone maturity that would be expected at the time of 
fetal insult in this model shouldn’t be ignored (Wu et al., 2006), as less-developed tissues 
(i.e. skeletal muscle) are more severely impacted by nutritional repartitioning. 
Nevertheless, when IUGR-born lambs were supplemented with clenbuterol or curcumin, 
their bodyweights and growth metrics were no longer impaired by 60 d of age. In fact, 
crown circumference-to-body girth ratios in IUGR-born juvenile lambs supplemented 
with curcumin indicate that the nutraceutical improved soft tissue-to-skeletal growth 
symmetry beyond that of our normal lambs. Furthermore, both supplements were 
effective in recovering poor weight gain in IUGR-born lambs, and curcumin 
supplementation recovered indicators of both skeletal and soft tissue growth. This shows 
that postnatal treatment with existing pharmaceuticals or nutraceuticals may be a viable 
strategy to increase feed efficiency, growth, and symmetrical body composition. This in 
turn could reduce the negative effects on wellbeing, metabolic efficiency, and carcass 
composition, thus recovering value in IUGR/low birthweight livestock. It is worth noting, 
however, that clenbuterol-supplemented and curcumin-supplemented IUGR lambs in this 
study did not exhibit the same reduction in birthweight as our unsupplemented IUGR 
lambs. In fact, curcumin-supplemented IUGR lambs had greater body girth, crown 
circumference, and crown circumference-to-body girth ratios than our controls at birth 
and maintained those advantages throughout the 60-d period. We speculate that this was 
due to the low power and inordinate number of singleton-born lambs relative to twins and 
triplets in these two groups.  
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At 60 d of age, the impact of IUGR on soft tissue growth was particularly evident 
postmortem. This was consistent with our observations at the neonatal stage (Cadaret et 
al., 2019c; Posont, 2019) and shows the persistent effect of nutrient repartitioning 
adaptions in the IUGR fetus on postnatal body composition. Nutrient repartitioning 
towards vital tissues is programmed by prenatal stress and leads to asymmetric growth 
(Alexander et al., 1987; Morrison, 2008) but is necessary to preserve vital organ function 
and prevent fetal death. Postnatal consequences of nutrient-sparing fetal adaptions are 
reflected in this study by the increased brain-to-bodyweight ratios in IUGR lambs at 60 d 
of age. Like bodyweight, however, clenbuterol and curcumin improved several key 
indicators of soft tissue-specific growth in IUGR lambs. Reduced lung-to-bodyweight 
ratios in IUGR juvenile lambs were recovered by clenbuterol supplementation, leading us 
to speculate that clenbuterol may improve growth of soft tissues beyond just muscle, as 
previously predicted (Von Deutsch et al., 2000). Unlike other metrics of asymmetry, 
however, brain-to-bodyweight ratios were not improved by postnatal clenbuterol or 
curcumin supplementation. Furthermore, kidney weights and kidney weight-to-
bodyweight ratios were diminished by both supplements, perhaps suggesting a negative 
impact of these products on kidney growth and/or function. In a recent case study, 
excessive clenbuterol use by an athlete in training increased the subject’s myoglobin in 
the bloodstream due to rhabdomyolysis, leading to secondary kidney damage (Grimmer 
et al., 2016). On the other hand, curcumin has been shown to improve chronic kidney 
disease in humans by preventing gut leakage of inflammatory biomolecules (Ghosh et al., 
2014) and thus its effects on kidney size here were unexpected. At 30 d of age, body 
composition and nutrient components estimated in the live animals by bioelectrical 
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impedance were not different among any groups in our study, which was surprising 
considering our previous observation of diminished lean mass and fat content at 25 d 
(Gibbs et al., 2019). The present findings may indicate that mild catch up growth had 
occurred by 30 d of age and persisted at 60 d of age. It is more likely, however, that the 
differences among groups were meager enough that we were unable to detect them 
through our estimations.  
As expected, loin muscle size and estimated lean mass was diminished in IUGR 
lambs at necropsy, which reflects the negative impact of prenatal stress on muscle growth 
capacity. Indeed, these observations were likely the product of reduced fetal myoblast 
proliferation (Yates et al., 2014) and impaired protein anabolism (Soto et al., 2017), 
which was clearly not recovered at the juvenile stage. Poor muscle growth at this stage 
helps to explain reduced yield and carcass merit that plagues IUGR/low birthweight 
livestock at harvest (Greenwood et al., 2000). However, clenbuterol supplementation 
increased the size of the loin in IUGR lambs, which provides some of the highest-value 
cuts in meat animals. This was perhaps not surprising, as it reflects the β2 agonist’s 
documented ability to enhance muscle growth in beef cattle and sheep (Johnson et al., 
2014). More surprisingly, however, was that estimated lean mass and loin size were also 
recovered by curcumin supplementation to IUGR lambs, although the mechanism by 
which it did so is not clear from these findings.  
Fat content is an important consideration when assessing the effectiveness of a 
postnatal IUGR treatment. Although, IUGR-born juvenile lambs had less total fat mass, 
their percentage of soft tissue that was comprised of fat was actually greater than 
controls. Based on previous findings in IUGR rats (Cettour-Rose et al., 2005), we 
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speculate that if these IUGR lambs had been assessed beyond the juvenile stage, their fat 
deposition would eventually reach the point that live-animal estimations for fat mass 
would reflect the observed increases in fat percentage. Curcumin supplementation 
lowered fat mass in IUGR lambs, which reflects the nutraceutical’s inhibitory effect on 
adipogenesis (Bradford, 2013). However, since bodyweight was not reduced at birth in 
supplemented IUGR lambs, differences in fat-to-protein ratios may more accurately 
represent body composition. Indeed, estimated and actual fat-to-protein ratios were 
increased in IUGR lambs, which reflects the adipose-driven pattern of postnatal catch up 
growth that arises from the reduced capacity for muscle growth (Cianfarani et al., 1999). 
Clenbuterol supplementation recovered estimated fat-to-protein ratios and increased 
protein content to the level of controls, which again reflects its ability to stimulate lean 
muscle growth (Johnson et al., 2014) and decrease lipogenesis (Miller et al., 1988). 
Despite its benefit to other growth indicators, curcumin supplementation did not elicit an 
effect on fat-to-protein ratios. 
The findings of this study allow us to conclude that the impact of IUGR on 
growth extends beyond early life and continues to be detrimental to juvenile-aged 
offspring. Specifically, IUGR persistently diminished morphometric indicators of soft 
tissue growth, which in turn altered body composition and reduced estimates of carcass 
merit. However, daily postnatal treatment with clenbuterol or curcumin demonstrated 
potential avenues to recover poor muscle growth and weight gain in IUGR-induced low 
birthweight livestock. Together, these findings show the potential for supplement-driven 
strategies to improve IUGR outcomes and justify further research to develop a more 
comprehensive and definitive understanding of their benefit to low birthweight livestock.  
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IMPLICATIONS  
 Lambs born with low birthweight due to IUGR continued to exhibit diminished 
bodyweight, muscle mass, feed efficiency, and carcass merit as juveniles. This shows that 
IUGR pathologies are persistent beyond early life. It also demonstrates the importance of 
developing preventative and therapeutic strategies to improve mechanisms of muscle 
growth and metabolic efficiency, which is perhaps the most effective approach to 
recovering value in low birthweight livestock. This study demonstrates that postnatal 
pharmaceutical and nutraceutical supplements may be a valid approach to improving 
diminished growth and body composition in IUGR offspring and warrant continued 
research.   
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Table 2-1. Sheep Balancer B136 Medicated Grain Diet. 
Ingredient  Amount 
Crude Protein (Min)a 36% 
1% 
11.50% 
4.50% 
Crude Fat (Min) 
Crude Fiber (Max) 
Calcium (Ca) (Min) 
Calcium (Ca) (Max) 5.50% 
Phosphorus (P) (Min) 0.85% 
Salt (NaCl) (Min) 2.50% 
Salt (NaCl) (Max) 3.50% 
Selenium (Se) (Min) 1.30 ppm 
Vitamin A (Min) 2000 IU/lb 
Lasalocid Sodiumb 136 g/ton 
aIncludes not more than 4.00% equivalent crude protein 
from non-protein nitrogen .  
bActive ingredient.  
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Table 2-2. Experimental groups assessed in this study. 
Group n Experimental Treatment Oral Carrier IV Carrier 
Curcumina 
(100mg/kg) 
Clenbuterolb 
(0.08μg/kg) 
Piperinec  
(20mg/kg) 
Corn Oild  
(1 ml) 
Salinee  
(1ml) 
Control 11 . . ✓ ✓ ✓ 
IUGR 6 . . ✓ ✓ ✓ 
IUGR + Curcumin 5 ✓ . ✓ ✓ ✓ 
IUGR + Clenbuterol 7 . ✓ ✓ ✓ ✓ 
a HerbaDiet, Akure Health Care, Haryana, India.    
b Mazola, ACH Food Companies Inc., Cordova, Tennessee 38016. 
c VetOne, MWI Veterinary Supply, Boise, Idaho 83705. 
d Puritan’s Pride, Puritans Pride Inc., Oakdale, New York, 11769-9001. 
e Sigma-Aldrich, St. Louis, Missouri, 63178. 
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Figure 2-1. Bodyweight (A) and average daily gain (B) measured over the first 60d of 
life in Control (n=15), IUGR (n=10), IUGR+Clenbuterol (n=7), and IUGR+Curcumin 
(n=4) lambs. Age differences in average daily gain (C) between the neonatal and juvenile 
stage. a,b means with differing superscripts differ (P<0.05). x,y means with differing 
superscripts tend to differ (P<0.10). 
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Figure 2-2. Average growth metric measured weekly (A) and crown-to-girth ratio at 
birth and 60d of age in Control (n=15), IUGR (n=10), IUGR+Clenbuterol (n=7), and 
IUGR+Curcumin (n=4) lambs. a,b means with differing superscripts differ (P<0.05). x,y 
means with differing superscripts tend to differ (P<0.10). 
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Table 2-3. Organ weights from IUGR lambs at 60 d of age. 
Variable Experimental Group  P-value 
 Control IUGR IUGR+Clenbuterol IUGR+Curcumin   
Hindlimb, g 180 ± 10x 150 ± 10y 180 ± 30x 180 ± 20x  0.09 
Hindlimb/BW, 
g/kg 82 ± 1
 82 ± 3 83 ± 3 83 ± 3  NS 
FDS, g 23.1 ± 1.2
x 18.0 ± 
1.5y 24.1 ± 4.8
xy 23.1 ± 1.6x  0.06 
FDS/BW, g/kg 
1.04 ± 
0.034 
0.97 ± 
0.082 1.12 ± 0.1 1.12 ± 0.091 
 NS 
Heart, g 189 ± 13x 135 ± 18y 136 ± 17y 93 ± 38y  0.09 
Heart/BW, g/kg 8.33 ± 0.33 
8.72 ± 
0.99 7.46 ±0.43 7.45 ± 1.51 
 NS 
Lungs, g 468 ± 34a 334 ± 22b 408 ± 41a 378 ± 57ab  0.03 
Lungs/BW, g/kg 
21.43 ± 
1.18a 
18.5 ± 
0.49b 20.51 ± 0.33
a 20.35 ± 1.59ab  0.02 
Liver, g 580 ± 34 503 ± 39 494 ± 57 492 ± 53  NS 
Liver/BW, g/kg 
25.92 ± 
1.14 
26.9 ± 
1.61 23.79 ± 0.67 25.00 ± 1.86 
 NS 
Kidney, g 71 ± 2
a 60 ± 4b 45 ± 2c 40 ± 7c  < 0.001 
Kidney/BW, 
g/kg 3.2 ± 0.07
a 3.23 ± 
0.15a 2.32 ± 0.23
b 2.35 ± 0.19b  < 0.001 
Brain, g 89 ± 2 86 ± 2 91 ± 3 93 ± 5  NS 
Brain/BW, g/kg 
4.04 ± 
0.19x 
4.74 ± 
0.17y 4.64 ± 0.33
y 4.79 ± 0.18y  0.07 
Values are expressed as means ± SE; BW, bodyweight; FDS, flexor digitorum superficialis; 
IUGR, intrauterine growth restriction; NS, not significant.  
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Table 2-4. Sex differences in organ weight of 60 d lambs regardless of experimental 
group. 
Variables Female Male  P-value 
Hindlimb, g 200 ± 10a 150 ± 10b  0.006 
Hindlimb/BW, g/kg 86 ± 2 82 ± 4  NS 
FDS, g 23.6 ± 1.3 20.5.0 ± 2.1  NS 
FDS/BW, g/kg 1.04 ± 0.04 1.08 ± 0.08  NS 
Heart, g 175 ± 10a 101 ± 29b  0.04 
Heart/BW, g/kg 7.30 ± 0.44 8.68 ± 0.88  NS 
Lungs, g 414 ± 20 379 ± 36  NS 
Lungs/BW, g/kg 17.92 ± 0.51a 22.50 ± 0.69b  < 0.001 
Liver, g 576 ± 24a 458 ± 50b  0.06 
Liver/BW, g/kg 25.49 ± 0.69 25.29 ± 1.24  NS 
Kidney, g 62 ± 2a 45 ± 5b  0.006 
Kidney/BW, g/kg 2.73 ± 0.08 2.82 ± 0.19  NS 
Brain, g 90 ± 1 89 ± 3  NS 
Brain/BW, g/kg 3.97 ± 0.12a 5.13 ± 0.23b  < 0.001 
Values are expressed as means ± SE; BW, bodyweight; IUGR, intrauterine growth 
restriction; NS, not significant.  
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Figure 2-3. BIA estimated fat-to-protein ratio (A), loin-eye area (B), proximate analysis 
measured protein and fat content (C) and proximate analysis measured fat-to-protein ratio 
from Control (n=11), IUGR (n=5), IUGR+Clenbuterol (n=7), and IUGR+Curcumin 
(n=3) lambs. a,b means with differing superscripts differ (P<0.05). x,y means with 
differing superscripts tend to differ (P<0.10). 
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Table 5. Body composition at 30 and 60 d of age and carcass composition at necropsy estimated by BIA 
in IUGR lambs. 
Variables Experimental Group  P-value 
 Control IUGR IUGR+Clenbuterol IUGR+Curcumin   
30 d of age       
FFM, kg 6.7 ± 1.11 6.32 ± 1.74 6.71 ± 1.1 6.78 ± 1.01  NS 
FFST, kg 7.61 ± 0.99 7.26 ± 1.50 7.52 ± 1.01 7.55 ± 0.94  NS 
CF, g 143.5 ± 2.6 140.6 ± 11.0 145.5 ± 9.6 139.5 ± 9.0  NS 
       
SUM, kg 6.1 ± 0.35 5.40 ± 0.5 6.00 ± 0.65 5.74 ± 0.37  NS 
LSLRS, kg 4.29 ± 0.25 3.82 ± 0.35 4.21 ± 0.44 4.04 ± 0.26  NS 
LSL, kg 2.17 ± 0.18 1.91 ± 0.25 2.12 ± 0.28 2.02 ± 0.19  NS 
       
Moisture, kg 8.79 ± 0.65 8.59 ± 0.82 8.94 ± 0.66 8.59 ± 0.61  NS 
Protein, kg 2.49 ± 0.22 2.36 ± 0.33 2.64 ± 0.26 2.52 ± 0.19  NS 
Fat, kg 1.61 ± 0.28 1.50 ± 0.35 1.65 ± 0.30 1.48 ± 0.27  NS 
Lean, kg 10.11 ± 0.83 9.63 ± 1.26 10.76 ± 0.99 10.33 ± 0.70  NS 
60 d of age      
 
FFM, kg 13.38 ± 0.97 10.09 ± 2.87 13.34 ± 2.19 14.77 ± 1.14  NS 
FFST, kg 13.88 ± 0.88 10.74 ± 2.70 13.73 ± 2.04 15.05 ± 1.04  NS 
CF, g 210.5 ± 9.5a 183.7 ± 16.4b 214.6 ± 25.2ab 236.8 ± 19.8a  < 0.001 
       
SUM, kg 10.19 ± 0.34a 8.46 ± 0.5b 9.97 ± 1.30ab 10.20 ± 0.63a  < 0.001 
LSLRS, kg 7.1 ± 0.24a 5.96 ± 0.57b 6.95 ± 0.9ab 7.15 ± 0.42a  < 0.001 
LSL, kg 4.0 ± 0.17a 3.22 ± 0.42b 3.91 ± 0.59ab 4.11 ± 0.29a  < 0.001 
       
Moisture, kg 13.48 ± 0.69 11.55 ± 1.28 13.88 ± 1.8 15.40 ± 1.38  NS 
Protein, kg 4.09 ± 0.23 3.56 ± 0.40 4.32 ± 0.61 4.78 ± 0.41  NS 
Fat, kg 3.77 ± 0.30a 2.88 ± 0.56b 3.89 ± 0.8ab 4.57 ± 0.62a  < 0.001 
Lean, kg 16.01 ± 0.83 14.15 ± 1.47 16.93 ± 2.23 18.59 ± 1.48  NS 
Necropsy       
FFM, kg 18.50 ± 0.49a 15.50 ± 0.55b 18.68 ± 1.34a 17.65 ± 0.78a  < 0.001 
FFST, kg 21.68 ± 0.48a 18.73 ± 0.58b 21.77 ± 1.66a 20.97 ± 0.87a  < 0.001 
CF, kg 160.2.5 ± 3.0a 137.2 ± 9.5b 165.7 ± 17.6a 156.8 ± 14.7ab  < 0.001 
       
SUM, kg 23.59 ± 0.54a 21.09 ± 0.74b 23.19 ± 2.31ab 22.96 ± 0.98a  < 0.001 
LSLRS, kg 15.13 ± 0.37a 13.44 ± 0.58b 14.86 ± 1.51ab 14.73 ± 0.65ab  < 0.001 
LSL, kg 9.34 ± 0.22a 8.34 ± 0.34b 9.18 ± 0.91ab 9.13 ± 0.37a  < 0.001 
       
Moisture, kg 10.47 ± 0.27a 8.75 ± 0.46b 10.92 ± 1.29a 10.38 ± 0.84a  < 0.001 
Protein, kg 3.37 ± 0.10a 2.73 ± 0.16b 3.60 ± 0.45a 3.43 ± 0.26a  < 0.001 
Fat, kg 2.27 ± 0.11a 1.54 ± 0.19b 2.41 ± 0.55a 2.14 ± 0.39a  < 0.001 
Lean, kg 13.71 ± 0.39a 11.31 ± 0.58b 14.63 ± 1.66a 14.02 ± 0.94a  < 0.001 
Values are expressed as means ± SE; FFM, fat-free mass (kg); FFST, fat-free soft tissue; CF, crude fat; 
IUGR, intrauterine growth restriction; NS, not significant. 
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Table 2-6. Spearman Correlations of ultrasound estimations of loin size with actual loin eye 
area. 
 Measurement  Ultrasound Estimates 
Ultrasound 
Estimate Loin eye Area
  Loin eye 
Area 
Back Fat Thickness Loin eye 
Depth 
Loin eye Area 0.48  . 0.01 0.74 
 (0.26)  . (0.99) (0.05) 
Back Fat Thickness 0.58  0.01 . 0.46 
 (0.16)  (0.99) . (0.3) 
Loin eye Depth 0.74  0.46 0.22 . 
 (0.05)  (0.3) (0.63) . 
Values are expressed as correlation coefficients with P-values italicized in parenthesis.  
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Chapter 3 
Deficits in skeletal muscle glucose metabolism and pancreatic islet β cell function in 
the IUGR juvenile lamb are improved by daily treatment with the β2 adrenergic 
agonist, clenbuterol HCl. 
ABSTRACT  
 Fetal metabolic programming associated with intrauterine growth restriction 
(IUGR) has been linked to deficits in skeletal muscle glucose metabolism and pancreatic 
β cell dysfunction throughout the neonatal stage. These adaptions disrupt physiological 
mechanisms that regulate energy substrate utilization and tissue responsiveness to 
metabolic stimuli. We hypothesized that these fetal programing deficits persist and 
potentially worsen as IUGR-born offspring reach the juvenile stage. We also postulated 
that these deficits could be mitigated postnatal through β adrenergic manipulation. Thus, 
the objective of this study was to determine if muscle-centric deficits in glucose 
metabolism and pancreatic β cell dysfunction progressively worsen at the juvenile stage 
and whether daily treatment with the β agonist clenbuterol is an effective strategy to 
improve glucose homeostasis and metabolic health IUGR-born offspring. At 60 d of age, 
basal hindlimb glucose oxidation tended to be reduced (P < 0.10) and insulin-stimulated 
hindlimb glucose oxidation was reduced (P < 0.05) in placental insufficiency-induced 
IUGR lambs compared to controls and clenbuterol-supplemented IUGR lambs. Basal 
hindlimb glucose uptake did not differ among groups and insulin-stimulated hindlimb 
glucose uptake was greater (P < 0.05) in clenbuterol-supplemented IUGR lambs than 
controls or unsupplemented IUGR lambs. In isolated flexor digitalis superficialis and 
soleus muscle, basal glucose oxidation rates were diminished (P < 0.05) in IUGR lambs 
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compared to controls. In soleus, basal glucose oxidation in clenbuterol-supplemented 
lambs was intermediate between controls and unsupplemented IUGR lambs. Insulin-
stimulated glucose oxidation rates were also diminished (P < 0.05) in both 
unsupplemented and clenbuterol-supplemented IUGR flexor digitalis superficialis and 
soleus muscle compared to controls. TNFα-stimulated glucose oxidation rates for isolated 
flexor digitalis superficialis did not differ between control and unsupplemented IUGR 
lambs but were less (P < 0.05) for clenbuterol-supplemented IUGR lambs than controls 
or unsupplemented IUGR lambs. TNFα-stimulated glucose oxidation rates for isolated 
soleus was less (P < 0.05) in IUGR lambs than controls and less (P < 0.05) in 
clenbuterol-supplemented IUGR lambs than unsupplemented IUGR lambs. Basal, 
insulin-stimulated, and TNFα-stimulated glucose uptake rates were all less (P < 0.05) in 
unsupplemented and clenbuterol-supplemented IUGR lambs than controls. Whole-body 
O2 consumption rates tended to be less (P = 0.07) and CO2 production was less (P < 0.05) 
in unsupplemented IUGR lambs than in controls or clenbuterol-supplemented IUGR 
lambs at 30 d of age, but neither differed among groups at 60 d of age. Basal insulin 
concentrations did not differ among groups at 60 d of age, but glucose-stimulated insulin 
secretion was reduced (P < 0.05) in unsupplemented IUGR lambs compared to controls 
and clenbuterol-supplemented IUGR lambs. This study shows that muscle-centric 
metabolic deficits and pancreatic islet dysfunction that persist in IUGR-born juvenile 
lambs can be improved by β adrenergic modification with daily clenbuterol treatment.  
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INTRODUCTION 
 Intrauterine growth restriction (IUGR) is the result of a compilation of fetal 
adaptions that are essential for fetal survival of poor in utero conditions but that also lead 
to intrinsic deficits in growth and metabolic function after birth (Barker et al., 1993; 
Cadaret et al., 2019c; Yates et al., 2019a). This fetal programming includes reduced 
skeletal muscle glucose metabolism that is compounded by pancreatic β-cell dysfunction, 
both of which contribute to an 18-fold increase in the risk for Metabolic Syndrome in 
adulthood (Limesand et al., 2007a; Gatford et al., 2010; Yates et al., 2018b; Posont, 
2019). Growth and metabolic adaptions can be attributed at least in part to changes in 
adrenergic and inflammatory signaling in muscle that continue even after the cessation of 
prenatal stress (Leos et al., 2010; Yates et al., 2011a). β2 adrenergic activity is a natural 
stimulant of skeletal muscle glucose oxidation (Cadaret et al., 2017) and is important for 
proper functional development of pancreatic islets (Macko et al., 2016a; Yates et al., 
2019a). Thus, we speculate that postnatal adrenergic manipulation could be effective in 
improving skeletal muscle glucose metabolism in IUGR-born offspring. We previously 
found that IUGR impairs oxidative mechanisms of glucose metabolism in fetal and 
neonatal skeletal muscle (Cadaret et al., 2018; Cadaret et al., 2019c; Posont, 2019; Yates 
et al., 2019a). These deficits in skeletal muscle are further compounded by altered 
pancreatic islet development and function, which restricts proper insulin secretion and 
disrupts whole-body insulin sensitivity (Limesand et al., 2007a). Moreover, neonatal 
metabolic deficits occurred in the absence of adipose-driven postnatal catch-up growth. 
This suggests that deficient glucose metabolism and insulin signaling is likely not the 
result of greater fat deposition but instead is due to programming adaptions induced by 
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prenatal stress proper (Cadaret et al., 2019c). In this study, we hypothesized that 
developmental adaptions in skeletal muscle glucose metabolism and pancreatic β cells 
persist or even worsen in IUGR-born lambs between the neonatal and juvenile ages, but 
that daily treatment with clenbuterol HCl, an injectable β2 agonist, could correct 
postnatal adrenergic regulatory tone and thus improve their metabolic function. 
Therefore, the objective of this study was to test this hypothesis by assessing in vivo and 
ex vivo skeletal muscle glucose metabolism, whole body oxidative metabolic indicators, 
and pancreatic β-cell function in IUGR-born lambs at 60 d of age. We also sought to 
determine if daily treatment with clenbuterol HCl would recover aspects of diminished 
skeletal muscle glucose metabolism by increasing β2 adrenergic tone.  
 
MATERIALS & METHODS  
Animals and Experimental Design  
These studies were approved by the Institutional Animal Care and Use Committee 
at the University of Nebraska-Lincoln, which is accredited by AAALAC International. 
Placental insufficiency-induced IUGR lambs were produced from Polypay crossbred 
ewes by the well-characterized maternal hyperthermia model described by Cadaret et al. 
(2019b) and Gibbs et al. (2020), and well as in the previous chapter. Briefly, timed-mated 
ewes were subjected to elevated ambient temperatures of 40°C with a relative humidity 
of 35% during peak placental development from the 40th to the 95th d of gestational age. 
Ewes were returned to thermoneutral temperatures (25°C) alongside their pair-fed control 
counterparts following the 55-d exposure, and all ewes were allowed to lamb naturally. 
At parturition, IUGR lambs were randomly assigned to receive 0.8μg/kg/d clenbuterol 
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HCl (i.m.) or a saline placebo of equal volume. All lambs were weaned at 12 hours of age 
and were hand-reared on milk replacer fed ad libitum for 30 days (Land O’Lakes Inc., 
Ardin Hills, MN) and then transitioned to the grain diet in Table 2. Milk replacer was 
discontinued by 45 d of age. At 55 d of age, lambs underwent surgical placement of 
indwelling catheters in the femoral artery and vein of one hindlimb as previously 
described (Yates et al., 2019a). A venous catheter and arterial perivascular blood flow 
probe were placed in the contralateral hindlimb. All catheters were exteriorized at the 
lamb’s flank. Arterial blood samples were taken daily from 55 to 60 d of age. Whole 
blood was analyzed for complete blood counts with a HemaTrue Veterinary Chemistry 
Analyzer (Heska, Loveland, CO) and for blood gases and metabolites with an ABL90 
Flex blood gas analyzer (Radiometer America, Bera, CA).  Lambs were euthanized at 60 
d of age by double barbiturate overdose.  
 
In vivo Metabolism   
 Indirect Calorimetry. To estimate whole body oxidative metabolism, O2 
consumption rates and CO2 production rates were determined by indirect calorimetry. At 
30 and 58 d of age, a sealed clear-plastic chamber was secured over the head of the lamb. 
Atmospheric air was pumped into the chamber through an inlet hose at a constant rate of 
110 L/min. O2 and CO2 content of air leaving the chamber through an outlet hose was 
measured with a Fox Box Respirometry System (Sable Systems, Las Vegas, NV). 
Measurements were obtained over two 30-min periods, each of which followed a 5-min 
baseline reading of atmospheric air. For the duration of this experiment, lambs were 
restrained in Panepinto slings to which they had been previously familiarized. Values for 
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O2 consumption rate (O2CR), CO2 production (CO2P), and metabolic rate (cal/hr) were 
averaged over the two periods.  
 Glucose-Stimulated Insulin Secretion. To measure β-cell function, glucose-
stimulated insulin secretion was determined during a square-wave hyperglycemic clamp 
at 58 d of age as previously described (Camacho et al., 2017). Briefly, a series of three 
baseline arterial blood samples were taken in 5-minute intervals. Afterward, an 
intravenous glucose bolus (150 mg/kg, i.v.) was administered followed by a continuous, 
variable-rate glucose infusion until the target steady-state glucose concentration (2.5X 
baseline glucose) was achieved. During steady-state hyperglycemia, another three arterial 
blood samples were taken in 5-min intervals. Blood samples collected into EDTA 
syringes were centrifuged (14,000 x g, 2 min, 4°C) to isolate plasma, which was then 
stored at -80°C. Bovine insulin ELISA (Alpco, Salem, NH) were then used to measure 
insulin concentrations in all plasma samples. Inter- and intra-assay CV were below 10%. 
Blood samples collected into heparin-coated syringes were analyzed using an ABL90 
Flex to measure glucose and lactate content.  
 Hindlimb Glucose Metabolism. At 59 d of age, hindlimb glucose metabolism was 
assessed during a hyperinsulinemic-euglycemic clamp (HEC) as previously described 
(Yates et al., 2019a). Briefly, lambs were bolused 2 ml of radiolabeled glucose tracer 
(18.75μCi/ml, U-[14C]-glucose; Perkin-Elmer, Waltham, MA) followed by a constant 
infusion of U-[14C]-glucose for 40 min at a rate of 2 ml/hr. Arterial and venous blood 
samples were simultaneously collected through femoral catheters in 5-minute intervals 
during the baseline period (4 total pairs of samples). Following baseline sample 
collection, a 6-ml glucose (150 mg/kg, i.v.) bolus and a 4-ml insulin (250 mU/kg; 
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Humulin-R, Eli Lilly, Indianapolis, IN) bolus were administered. Glucose was constantly 
infused at variable rates to maintain euglycemia (±10% baseline) and insulin was infused 
at a constant rate of 0.5 ml/hr/kg. Once steady-state HEC was achieved for 2 hours, four 
more pairs of simultaneously-collected arterial and venous blood samples were taken in 
5-minute intervals. Plasma was collected and stored at -80°C and insulin concentrations 
were determined by Bovine Insulin ELISA. Blood samples were analyzed for blood 
gasses and metabolites. To measure hindlimb glucose oxidation, additional arterial and 
venous blood was placed in micro-centrifuge tubes containing 2M HCl and suspended 
within a 20-ml scintillation vial containing 1M NaOH at the bottom. These vials were 
sealed and incubated at room temperature. During a 24-hr incubation, HCl caused the 
release of CO2 from the blood sample, which was then recaptured by the NaOH at the 
bottom of the scintillation vial. Following the incubation period, the blood-filled 
microcentrifuge tubes were removed, and scintillation vials were filled with UltimaGold 
scintillation fluid (Perkin-Elmer). Radiolabeled CO2 (14CO2) concentrations were 
quantified using a Beckman-Coulter 1900 TA LC counter (Brea, CA). Glucose oxidation 
rates were then determined from the difference in 14CO2 concentration between each 
arterial and venous blood sample pair. The amount of glucose oxidized was calculated in 
nmol using the specific activity of 14C in the infusate, and these values were normalized 
to hindlimb mass and femoral artery blood flow rate at the time of sample collection. 
Hindlimb glucose uptake rates were estimated by the difference in arterial and venous 
glucose concentrations, normalized to hindlimb mass and blood flow rate. 
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Ex vivo Skeletal Muscle Glucose Metabolism  
At 60 d of age, lambs were euthanized and the flexor digitorum superficialis and 
soleus muscles were collected for ex vivo metabolic analysis. Muscles were split tendon-
to-tendon into 500 ± 50 mg strips. Strips were pre-incubated for 1 hr in Krebs-Heneslit 
Buffer (KHB) with no additive (basal), insulin (5 mU/ml Humulin-R), or TNFα (10 
ng/ml). Following pre-incubation, muscle strips were washed in glucose-free KHB with 
the respective additive for 20 min. To measure glucose oxidation, muscle strips were 
placed in sealed dual-well chambers and incubated in KHB media containing the 
respective additive and 5 mM [14C-U] D-glucose for 2 hr. The adjacent well of each 
chamber contained 1M NaOH. After 2 hr, chambers were cooled and wells containing 
muscle strips were injected with 2M HCl and allowed to incubate at 4°C for an additional 
2 hr, during which bicarbonate-bound 14CO2 was freed from the media and captured by 
the NaOH in the adjacent well. NaOH was collected and 14CO2 concentration was 
determined by liquid scintillation. To measure glucose uptake, muscle strips were 
incubated in KHB media containing the respective additive and 1 mM [3H]2-
deoxyglucose for 20 min. After the 20 min incubation, muscle strips were cooled, 
washed, and lysed by incubation in 2M NaOH. The concentration of [3H]2-deoxyglucose 
for each lysate was then determined by liquid scintillation. 
  
Statistical Analysis  
 All data were analyzed using the Mixed procedure of SAS (SAS Institute, Cary, 
NC) with lamb as the experimental unit. Variables in GSIS, HEC, and ex vivo studies 
were analyzed for effects due to treatment, period (or incubation condition), and the 
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interaction, with period/incubation condition treated as repeated variables. For GSIS and 
HEC studies, samples within each period (technical replicates) were averaged for each 
lamb. Likewise, the 3 technical replications/condition for each lamb in ex vivo studies 
were averaged. Data are presented as means ± SEM. 
 
RESULTS 
Hematology 
 No experimental group x day interactions were observed for any hematology 
components. Total white blood cells (WBC), monocyte, lymphocyte, and granulocyte 
concentrations were not different among experimental groups (Figure 3-1). Hematocrit 
(Figure 3-2A), red blood cell concentrations (Figure 3-2B), and platelet concentrations 
(Figure 3-2C) were increased (P < 0.05) in unsupplemented IUGR lambs and reduced (P 
< 0.05) in clenbuterol-supplemented IUGR lambs compared to controls. Mean 
corpuscular volume (Figure 3-2D) and mean platelet volume (Figure 3-2E) were less (P 
< 0.05) in unsupplemented IUGR lambs but greater (P < 0.05) in clenbuterol-
supplemented IUGR lambs compared to controls. Hemoglobin concentration did not 
differ between controls and unsupplemented IUGR lambs but were less (P < 0.05) in 
clenbuterol-supplemented IUGR lambs than controls (Figure 3-3A). Carbon dioxide-
bound hemoglobin was greater (P < 0.05) in all IUGR lambs compared to controls but to 
a larger (P < 0.05) degree in clenbuterol-supplemented IUGR lambs (Figure 3-3D). 
Mean corpuscular hemoglobin concentration (Figure 3-3B) and oxygen bound 
hemoglobin concentration (Figure 3-3C) were not different among experimental groups. 
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Blood Gases and Metabolites 
 There were no differences in daily blood glucose (Figure 3-4A), plasma insulin 
(Figure 3-4B), glucose-to-insulin ratio (Figure 3-4C), or blood lactate concentrations 
(Figure 3-4D) among experimental groups. Blood pH did not differ between controls and 
unsupplemented IUGR lambs but was reduced (P < 0.05) in clenbuterol-supplemented 
IUGR lambs (Figure 3-5C). We also observed experimental group x day interactions for 
CO2 partial pressure (pCO2; Figure 3-5D), O2 partial pressure (pO2; Figure 3-5E), O2-
bound hemoglobin (Figure 3-3B), and HCO3 concentrations (Figure 3-5B). pCO2 was 
lower (P < 0.05) in unsupplemented IUGR lambs than controls on d 56 and 57 but not on 
d 58, 59, and 60. pCO2 in clenbuterol-supplemented IUGR lambs was lower (P < 0.05) 
than controls on d 56, greater (P < 0.05) on d 60, and not different on d 57, 58, and 59. 
HCO3 concentrations were lower (P < 0.05) for both unsupplemented and clenbuterol-
supplemented IUGR lambs than controls on d 57 but not different on d 56 and 60. HCO3 
was also less (P < 0.05) in clenbuterol-supplemented IUGR lambs than controls on d 59 
and less (P < 0.05) than unsupplemented IUGR lambs on d 58. pO2 was greater (P < 
0.05) in unsupplemented IUGR lambs than controls on d 56, 57, 59, and 60 but not on d 
58. pO2 was also greater (P < 0.05) in clenbuterol-supplemented IUGR lambs compared 
to controls on d 56, 58, and 60, and was lower (P < 0.05) compared to unsupplemented 
IUGR lambs on d 60. O2-bound hemoglobin was greater (P < 0.05) for both 
unsupplemented and clenbuterol-supplemented IUGR lambs compared to controls on 
each day. O2-bound hemoglobin was also greater (P < 0.05) for clenbuterol-
supplemented IUGR lambs than unsupplemented IUGR lambs on d 57 but less (P < 0.05) 
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on d 60. Potassium concentrations tended to be less (P = 0.08) in unsupplemented IUGR 
lambs compared to controls but did not differ between controls and clenbuterol-
supplemented IUGR lambs. Sodium and calcium concentrations did not differ among 
experimental groups.  
 
Whole-body Oxidative Metabolism 
At 30 d of age, OCR tended to be less (P = 0.07) and CO2P was less (P < 0.05) in 
unsupplemented IUGR lambs compared to controls but did not differ between 
clenbuterol-supplemented IUGR lambs and controls (Figure 3-6A). At 60 d of age, there 
were no differences among experimental groups for OCR or CO2P. Metabolic rates did 
not differ among experimental groups at 30 or 60 d (Figure 3-6A, 3-6B, 3-6C). OCR, 
CO2P, and metabolic rates were reduced (P < 0.05) at 60 d compared to 30 d of age, 
regardless of experimental group.  
 
Glucose-Stimulated Insulin Secretion 
 An experimental group x day interaction was observed (P < 0.05) for plasma 
insulin but not for blood glucose, blood lactate, or glucose-to-insulin ratio. Blood glucose 
and blood lactate (Figure 3-7B) concentrations did not differ among experimental 
groups, but were greater (P < 0.05) during hyperglycemia than under basal conditions. 
Basal plasma insulin concentrations (Figure 3-7A) did not differ among groups, but 
glucose-stimulated insulin secretion was lower (P < 0.05) in unsupplemented IUGR 
lambs compared to controls and clenbuterol-supplemented IUGR lambs. Glucose-to-
insulin ratios were increased (P < 0.05) for unsupplemented and clenbuterol-
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supplemented IUGR lambs compared to controls, regardless of glycemic conditions 
(Figure 3-7C). They were also reduced (P < 0.05) under hyperglycemic conditions 
compared to basal conditions, regardless of experimental group (Figure 3-7D).  
 
Hindlimb Glucose Metabolism 
 Hindlimb glucose uptake rates and blood lactate concentrations were not different 
among experimental groups under basal conditions but both were greater (P < 0.05) in 
clenbuterol-supplemented IUGR lambs than controls or unsupplemented IUGR lambs 
under HEC conditions (Figure 3-8A and B). Insulin sensitivity for glucose uptake was 
also not different among experimental groups (Figure 3-9A). Hindlimb glucose oxidation 
tended to be reduced (P = 0.10) under basal conditions and was reduced (P < 0.05) under 
HEC conditions for unsupplemented IUGR lambs compared to controls and clenbuterol-
supplemented IUGR lambs (Figure 3-8C). Insulin sensitivity for glucose oxidation was 
increased (P < 0.05) in unsupplemented IUGR lambs compared to controls but did not 
differ between clenbuterol-supplemented IUGR lambs and controls (Figure 3-8D).  
 
Ex Vivo Skeletal Muscle Glucose Metabolism 
 Glucose uptake rates were less (P < 0.05) for FDS muscle from unsupplemented 
and clenbuterol-supplemented IUGR lambs than FDS from controls in all media 
conditions (Figure 3-10A). Basal glucose oxidation rates were less (P < 0.05) for FDS 
and soleus muscles from unsupplemented IUGR lambs and for FDS from clenbuterol-
supplemented IUGR lambs compared to those from controls. Basal oxidation in soleus 
muscle from clenbuterol-supplemented IUGR lambs was intermediate between controls 
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and unsupplemented IUGR lambs (Figure 3-10B). When incubated in insulin-spiked 
media, glucose oxidation rates were less (P < 0.05) for FDS and soleus from 
unsupplemented IUGR lambs and soleus from clenbuterol-supplemented IUGR lambs 
compared to those from controls (Figure 3-10B). When incubated in TNFα-spiked 
media, glucose oxidation rates were lower (P < 0.05) for soleus from unsupplemented 
IUGR lambs and for FDS and soleus from clenbuterol-supplemented IUGR lambs 
compared to those from (Figure 3-10B).  
 
DISCUSSION  
The results of this study demonstrate that muscle-specific deficits in glucose 
metabolism caused by placental insufficiency-induced IUGR continue to be exhibited by 
juvenile-aged offspring, despite improvement in whole-body oxidative metabolism 
between the neonatal and juvenile stages. In vivo and ex vivo metabolic studies indicated 
that impaired hindlimb glucose metabolism in addition to deficits in pancreatic β cell 
function persisted in juvenile lambs that were born IUGR. These results parallel our 
previous findings in the neonate in which hindlimb glucose metabolism was restricted by 
PI-IUGR, resulting in reduced hindlimb and primary skeletal muscle glucose oxidation 
under basal and insulin-stimulated conditions (Cadaret et al., 2019c). As with fetal and 
neonatal stages (Limesand et al., 2007b; Cadaret et al., 2019c), the deficits we observed 
in glucose oxidative metabolism at the juvenile stage appeared to be independent of 
glucose uptake. They also appeared to be associated with abhorrent insulin and cytokine 
sensitivity in muscle tissues. Despite the continuance of metabolic deficits in IUGR-born 
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offspring beyond early life, this study also showed that some metabolic deficits can be 
improved through daily treatment of the β2 adrenergic agonist, clenbuterol.  
In vivo assessment of skeletal muscle glucose metabolism revealed that IUGR 
fetal adaptions continued to reduce hindlimb glucose oxidation through 2 mo. of age. 
Similar to our previous studies in the neonate (Cadaret et al., 2019c; Posont et al., 2019; 
Yates et al., 2019b), reductions in hindlimb glucose oxidation were independent of 
glucose uptake. Clenbuterol was particularly effective in recovering diminished hindlimb 
glucose metabolism, which was reflected in the recovery of both basal and insulin-
stimulated glucose oxidation. In fact, clenbuterol reduced blood lactate levels during 
hyperinsulinemia, increased basal CO2-bound hemoglobin, and reduced basal blood pH, 
all of which are consistent with the increase in oxidative metabolism. In addition to 
improvements in skeletal muscle glucose oxidation, clenbuterol also increased glucose 
uptake by the hindlimb tissues of our IUGR lambs beyond the rates observed in our 
normal lambs. The recovery of normal hindlimb glucose oxidation coupled with 
increased hindlimb glucose uptake rates and reduced blood lactate concentrations suggest 
that increasing the β2 adrenergic activity in our IUGR-born lambs helped to correct their 
muscle-specific deficits in glucose metabolism. This also further validates our long-
standing speculation that β adrenergic dysfunction is prevalent in IUGR skeletal muscle 
(Yates et al., 2011b; Yates et al., 2012b; Yates et al., 2018a; Posont and Yates, 2019).  
Our ex vivo analysis demonstrated the muscle-specific nature of the IUGR-
associated deficits in glucose uptake and oxidation in two muscles of the hindlimb with 
very different metabolic phenotypes. Interestingly, the benefits of clenbuterol on glucose 
metabolism that were observed in vivo were not recapitulated in ex vivo primary skeletal 
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muscle glucose uptake and oxidation. This leads us to believe that β adrenergic modifiers 
may lose their effect once the muscle is no longer being exposed to them and thus they 
may require continuous administration to improve IUGR deficits long term. In addition, 
clenbuterol supplementation further diminished TNFα-stimulated glucose oxidation in 
IUGR lambs, which further represents the adrenergic system’s inhibitory effect on 
inflammatory cytokine action.  
Indicators of whole-body total oxidative metabolism were reduced in our IUGR-
born lambs when assessed during the neonatal stage, but these differences had 
disappeared by 60 d of age, which suggests that total oxidative metabolism improves as 
neonates grow and mature into the juvenile stage, despite persistent reductions skeletal 
muscle glucose oxidation. We speculate that this improvement is likely the result of 
compensatory increases in protein and lipid oxidation and/or greater non-muscular 
glucose oxidation that offset the known reduction in glucose oxidative capacity of IUGR 
skeletal muscle.  
This study also showed that pancreatic β cell response under hyperglycemic 
conditions continued to be impaired in IUGR-born offspring at the juvenile stage. Much 
like in the fetus and neonate (Cadaret et al., 2019a; Cadaret et al., 2019c), insulin 
secretion was not altered under resting glycemic conditions, suggesting that it is the 
stimulus-secretion coupling for insulin that is disrupted. Interestingly, proper insulin 
secretion and islet sensitivity to glucose were achieved by increasing β2 adrenergic 
activity with daily clenbuterol supplementation, despite insulin secretion being primarily 
modulated by α2 adrenoceptor binding (Limesand and Rozance, 2017a). In addition, 
glucose-to-insulin ratios were increased for both unsupplemented and clenbuterol-
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supplemented IUGR lambs. This along with no differences in insulin sensitivity for 
glucose uptake suggests that peripheral tissue responsiveness to insulin stimulation might 
be impaired in the 60-d IUGR-born lamb in addition to β-cell function, as previously 
observed in the IUGR fetus (Limesand et al., 2007a).  
From the results of this study, we can conclude that IUGR fetal adaptions 
continue to pose consequences for skeletal muscle glucose metabolism and pancreatic β 
cell function as offspring advance to the juvenile stage. However, these adaptive 
programming mechanisms appear to be at least partially recovered by daily treatment 
with the β2 agonist, clenbuterol. This study further demonstrates that IUGR-born 
offspring are restricted by β adrenergic dysfunction, which disrupts important regulatory 
mechanisms that are necessary for proper skeletal muscle glucose oxidation and insulin 
responses. In addition, this study provides evidence that postnatal treatment of metabolic 
deficits associated with IUGR is on target to prevent or reduce the risk of later life 
metabolic disease.  
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Figure 3-1. Daily total white blood cell (A), monocyte (B), lymphocyte (C), and 
granulocyte (D) concentrations from Control (n=11), IUGR (n=5), and 
IUGR+Clenbuterol (n=7) juvenile lambs. 
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Figure 3-2. Daily hematocrit percentage (A), red blood cell concentration (B), platelet 
concentration (C), and mean corpuscular volume (D) from Control (n=11), IUGR (n=5), 
and IUGR+Clenbuterol (n=7) juvenile lambs. a,b means with differing superscripts differ 
(P<0.05). 
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Figure 3-3. Daily hemoglobin (A), oxygen bound hemoglobin (B), mean corpuscular 
hemoglobin, and carbon dioxide bound hemoglobin (D) concentrations from Control 
(n=11), IUGR (n=5), and IUGR+Clenbuterol (n=7) juvenile lambs. a,b means with 
differing superscripts differ (P<0.05). 
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Figure 3-4. Daily blood glucose (A), plasma insulin concentration (B), and glucose-to-
insulin ratio (C) from Control (n=11), IUGR (n=5), IUGR+Clenbuterol (n=7) juvenile 
lambs. 
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Figure 3-5. Daily blood lactate (A), blood bicarbonate (B), blood pH (C), partial pressure 
carbon dioxide (D), and partial pressure oxygen (E) concentrations from Control (n=11), 
IUGR (n=5), and IUGR+Clenbuterol (n=7) juvenile lambs. a,b means with differing 
superscripts differ (P<0.05). 
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Figure 3-6. Whole body oxidative metabolism measured by oxygen consumption rate 
(A), carbon dioxide production rate (B), and metabolic rate (C) from Control (n=11), 
IUGR (n=6), and IUGR+Clenbuterol (n=7) juvenile lambs. a,b means with differing 
superscripts differ (P<0.05). 
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Figure 3-7. Plasma insulin concentration (A), blood lactate concentration (B), and 
glucose-to-insulin ratio (D) under basal and hyperglycemic conditions. Average glucose-
to-insulin ratio (C) was measured over both periods from Control (n=11), IUGR (n=5), 
and IUGR+Clenbuterol (n=6) juvenile lambs. a,b means with differing superscripts differ 
(P<0.05). 
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Figure 3-8. Hindlimb glucose uptake (A), hindlimb blood lactate (B), and hindlimb 
glucose oxidation (C) under basal and hyperinsulinemic-euglycemic conditions measured 
by an in vivo Hyperinsulinemic-Euglycemic Clamp study. Hindlimb plasma insulin 
concentrations during steady-state hyperinsulinemia was measured by Bovine ELISA for 
Control (n=8), IUGR (n=5), and IUGR+Clenbuterol (n=6) juvenile lambs. a,b means with 
differing superscripts differ (P<0.05). 
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Figure 3-9. Insulin sensitivity for hindlimb glucose uptake (A) and hindlimb glucose 
oxidation (B) during steady-state hyperinsulinemia measured by fold change percentage 
between basal and hyperinsulinemic-euglycemic conditions. Data shown are from 
Control (n=8), IUGR (n=5), and IUGR+Clenbuterol (n=6) juvenile lambs. a,b means with 
differing superscripts differ (P<0.05). 
 
 
  
   86 
 
Figure 3-10.  Ex vivo glucose metabolism by primary skeletal muscle collected at 60d of 
age from Control (n=11), IUGR (n=5), and IUGR+Clenbuterol (n=7). Data are shown for 
juvenile flexor digitorum superfalisis muscle glucose uptake rates (A.), solues muscle 
glucose oxidation rates (B.) and flexor digitorum superfalisis muscle glucose oxidation 
rates (C.) after incubation in media without (basal), with 5mU/ml insulin or 10ng/ml 
TNFα. a,b means with differing superscripts differ (P<0.05). 
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Chapter 4 
Body composition estimated by bioelectrical impedance analyses (BIA) is 
diminished by prenatal stress in neonatal lambs and by heat stress in feedlot 
wethers.2 
 
2A version of this chapter containing minimal modification was previously published in 
Translational Animal Science: 2019 Dec;3(Suppl 1):1691-1695. doi: 10.1093/tas/txz059. 
 
ABSTRACT 
Stress during postnatal growth or during critical windows of prenatal development 
reduce muscle mass and alter body composition. Lean-to-fat proportion is indicative of 
wellbeing, performance, and value in livestock. Bioelectrical impedance analysis (BIA) 
is an accurate and objective tool for assessing body composition in humans. Our 
objective was to determine the impact of stress on BIA-estimated body composition in 
neonatal lambs exposed to in utero stress and in heat-stressed feedlot wethers. In Exp.1 of 
this study, intrauterine growth-restricted (IUGR) lambs were produced by maternal 
hyperthermia-induced placental insufficiency (PI-IUGR) or bacterial endotoxin-induced 
maternal inflammation (MI-IUGR). A 2nd group of PI-IUGR ewes were supplemented 
with 100% O2 (10L/min, endotracheal) for the last 3 wk of gestation (PI-IUGR+O2). BIA 
was performed at d 3 and 25 after birth. Bodyweight (BW) at d 3 and 25 was lower (P < 
0.05) in PI-IUGR and MI-IUGR lambs but not PI-IUGR+O2 lambs compared to controls. 
At 3 d, BIA did not detect differences among groups for fat-free mass (FFM) or carcass 
components, and estimates were inconsistent and unrealistic. At 25 d, however, BIA 
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indicated that FFM/BW, moisture content, and fat content were reduced (P < 0.05) and 
protein content tended to be reduced (P < 0.10) in PI-IUGR and MI-IUGR lambs 
compared to PI-IUGR+O2 and controls. In Exp.2 of this study, feedlot wethers were 
exposed to heat stress (40°C, 35% RH) or thermoneutral conditions for 30 d, and BIA 
was performed on d 0 and 14 in the live animal and on d 30 in the un-chilled carcass. 
Average daily gain tended to be less (P < 0.08) in heat-stressed wethers. At d 0 and 14, 
BIA did not detect differences for any body composition estimates. At d 30, postmortem 
FFM/BW in heat-stressed wethers was ~6.6% less (P < 0.05) and FFST/BW was ~6.5% 
less (P < 0.05) than control wethers. Carcass components did not differ between groups. 
From these studies, we conclude that BIA reasonably estimates stress-induced changes in 
body composition in lambs, except in very young animals. 
 
INTRODUCTION 
In livestock, body composition plays an intricate role in productivity and 
profitability. Previous research has shown that carcass traits are highly heritable, thus the 
benefit of estimating body composition in the live animal is substantial (Berg et al., 
1994). Bioelectrical impedance analysis (BIA) is used in humans to assess body 
composition (Khlaed et al., 1988) but is used less in livestock. BIA outputs for electrical 
flow through tissues are fit to regression equations that predict fat-free mass (FFM) or 
fat-free soft tissue (FFST) (Lukaski et al.,1985), which estimate the amount of lean body 
mass relative to fat. FFM and FFST indicate value for food animal producers. Poor body 
composition (high fat, less lean mass) can be caused by stress in growing lambs (Lukaski 
et al.,1985; Jenkins et al., 1988) and in utero, which has detrimental effects on muscle 
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growth and metabolic function of offspring later in life (DeBlasio et al., 2007; Barker and 
Hales, 1992). Intrauterine growth restriction (IUGR) is caused by placental insufficiency, 
and heat stress is a leading cause of placental insufficiency in livestock (Chen et al. 
2010). In animal models, it restricts fetal growth by 30 to 60% (Brown et al., 2015; 
Macko et al., 2016). Maternal inflammation, another common stress factor in both 
humans and animals, restricts growth by 24% (Cadaret et al., 2018). IUGR increases 
perinatal mortality and morbidity and is characterized in offspring by low birthweight and 
asymmetrical body composition due to impaired muscle growth (Yates et al., 2018). The 
objective of this study was to determine whether BIA measurements can predict changes 
to body composition in live sheep for use in the food production industry as well as to 
determine if BIA measurements reflect stress-induced changes.  
 
MATERIALS & METHODS 
Animals and Experimental Design   
The following experiments were approved by the Institutional Animal Care and 
Use Committee at the University of Nebraska-Lincoln. Studies were conducted at the 
University of Nebraska-Lincoln Animal Science Complex, which is accredited by 
AAALAC International. 
Expetriment 1. Maternal inflammation-induced IUGR (MI-IUGR; n = 8) lambs 
were produced from time-mated Polypay ewes administered E.coli O55:B5 bacterial 
lipopolysaccharide (0.1µg/kg, i.v.; Sigma-Aldrich) every 3rd day from the 100th to the 
115th day of gestation (dGA), as previously described (Cadaret et al., 2019). Placental 
insufficiency-induced IUGR (PI-IUGR; n = 7) lambs were produced from ewes exposed 
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to 40°C and 35% RH from dGA 40 to dGA 90, as previously described (Yates et al., 
2019). A second group of PI-IUGR lambs was produced from ewes that were also 
supplemented with maternal O2 through an endotracheal catheter for 8 h/d from dGA 131 
until parturition (PI-IUGR+O2; n = 9). Controls were maintained at thermoneutral 
conditions and injected with saline carrier only (n = 16). Lambs were weaned at birth and 
hand reared on milk replacer fed ad libitum. BIA was performed on all lambs at 3 d and 
25 d of age.  
Experiment 2. Suffolk crossbred wethers (approximately 5 mo of age, 43.1  ±0.6 
kg) were commercially purchased. Wethers were stratified by bodyweight (BW) and 
randomly assigned to be individually penned under thermoneutral (controls; n = 14) or 
heat-stress (n = 12) conditions. Heat stress (35°C x 12 h/d and 40°C x 12 h/d, 35% RH) 
was induced for 30 d following a 2-d temperature step-up. Controls were maintained at 
25°C and 15% humidity. Ractopamine HCl was supplemented to half of each group in a 
2 x 2 factorial but had no effect on the results of this study, so it was removed from the 
model. Additional data from these lambs has been published elsewhere (Swanson et al., 
2020). 
 
Bioimpedance Analysis  
In Experiment 1, BIA was performed in the live lambs at 3 and 25 d of age. In 
Experiment 2, BIA was performed in the live wethers on d 0 and d 14 of the study period 
and in the hot carcasses at necropsy. We utilized a four-terminal Quantum V impedance 
apparatus, (RJL Systems, Detroit, MI) that measures reactance (Xc), resistance (Rs), and 
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phase angle (PA). This machine utilizes two sets of spaced electrode-terminals that 
transmit an electrical current through the tissues, which is detected by electrodes placed 
at another location on the body. Aluminum 20G MONOJECTTM needles (Covidien llc, 
Mansfield, MA) were placed SQ in the live animal and IM in the hot carcass and 
connected to the electrodes. The two sets of electrode-terminals (one red and one black) 
were placed 2.5 cm apart from each other. In live animals, one set was placed at the upper 
back, approximately 10 cm from the point of the scapula. The 2nd set was placed at the 
lower back, approximately 5 cm from the tail head. Both sets were placed dorsally, 
approximately 1 cm off the midline. Measurements were recorded for 30 consecutive 
seconds, with one measurement every 5 seconds, resulting in six total measurements. 
These were averaged and used in estimation equations outlined in Table 4-1 for live 
animal mass and nutrient composition. For wether carcasses, electrodes were placed in 
the same approximate location as in the live animal. Body composition was estimated 
using the previously-determined equations in Table 4-1.  
 
Proximate Analysis  
Proximate analysis was performed on the longissimus dorsi (i.e. loin muscle) of 
wethers in Experiment 2 by Midwest Laboratories (Omaha, NE) to determine moisture, 
fat, and protein content. These were compared to BIA-estimated values.  
 
Statistical Analysis   
All data were analyzed by ANOVA using the mixed procedure of SAS. For BIA 
data, age of the animal was treated as a repeated measure. Lamb was considered the 
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experimental unit for Experiment 1 and wether for Experiment 2. Mean FFM and FFST 
were calculated from the average of their respective equations. Data are presented as 
means ± standard error. 
 
RESULTS  
Experiment 1.  
BIA-estimated body composition and nutrient content for neonatal lambs are 
presented in Table 2. At 3 and 25 d of age, BW was less (P < 0.05) for MI-IUGR and PI-
IUGR lambs than for controls and PI-IUGR+O2 lambs. BW was also less (P < 0.05) in 
PI-IUGR lambs than MI-IUGR lambs at 3 d of age but not at 25 d of age. At 3 d of age, 
BW/body length (BL) was less (P < 0.05) in PI-IUGR lambs than controls, MI-IUGR 
lambs, and PI-IUGR+O2 lambs. At 25 d of age, BW/BL was less (P < 0.05) in PI-
IUGR+O2 and MI-IUGR lambs than controls and PI-IUGR lambs. BIA-estimated 
moisture content was less (P < 0.05) for PI-IUGR and MI-IUGR lambs than for controls 
and PI-IUGR+O2 lambs at 3 and 25 d of age. Estimated moisture was also less (P < 0.05) 
in PI-IUGR lambs than in MI-IUGR lambs at 3 d but not 25 d. Estimated protein content 
was not different among groups and estimated fat content could not be estimated at 3 d, 
but both were less (P < 0.05) in PI-IUGR and MI-IUGR lambs than in controls and PI-
IUGR+O2 lambs at 25 d. Estimated moisture content/BW and protein content/BW did not 
differ among groups at either day. Estimated fat content/BW was less (P < 0.05) in PI-
IUGR lambs than in controls, PI-IUGR+O2, and MI-IUGR at 25 d of age. BIA-estimated 
FFM was not different among groups at 3 d but tended to be less (P < 0.10) in PI-IUGR 
and MI-IUGR lambs than controls at 25 d. FFM was also less (P < 0.05) in PI-IUGR 
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lambs than in PI-IUGR+O2 lambs. FFM/BW was less (P < 0.05) in PI-IUGR lambs than 
in controls, PI-IUGR+O2, and MI-IUGR lambs at 25 d of age. 
Experiment 2.  
BIA-estimated body composition measured in the live animal is presented in 
Table 3 and that measured at necropsy is presented in Table 4. There were no differences 
between controls and heat-stressed wethers for any BIA-estimated body composition 
variables (FFM, FFST, muscle yield) on d 0 or d 14 of the study. Average daily gain 
(ADG) between d 0 and d 14 and between d 0 and d 30 (Tables 3 and 4, respectively) 
tended to be less (P < 0.10) in heat-stressed weathers than in controls. None of the four 
equations for FFM or three equations for FFST detected differences between groups at d 
0 or d 14. Likewise, no differences were observed for FFM/BW or FFST/BW. At 
necropsy, there were no differences between control and heat-stressed wethers for 3 of 4 
FFM equations and for 2 of 3 FFST equations. However, the FFM4 equation, the FFST2 
equation, and the mean for FFM and FFST detected reductions (P < 0.05) or tendencies 
for reductions (P < 0.10) in heat-stressed wethers compared to controls. Moreover, 
FFM/BW and FFST/BW were reduced (P < 0.05) in heat-stressed wethers compared to 
controls for all equations as well as the respective means of the equations. Estimated sum 
of the leg, sirloin, rack, shoulder, neck, riblets, shank, and lean trim mass (SUM), the sum 
of leg, sirloin, loin, rack, and shoulder mass (LSRLS), and the sum of leg, sirloin, and 
loin mass (LSL) were not different between groups. Nutrient composition (moisture, 
protein, fat, lean mass) estimated for heat-stressed wethers at d 0 and d 14 is presented in 
Table 5. No differences between controls and heat-stressed wethers were observed at 
either day.  
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DISCUSSION 
Our findings show that the impact of prenatal stress on body composition in 
offspring was detectable at 25 d of age but not at 3 d of age. Reduced lean tissue mass is 
a hallmark characteristic of IUGR and is often coupled with increased fat deposition 
during early postnatal growth (Yates et al., 2018). The reduced fat mass estimated in 
IUGR lambs at 25 d of age shows that they had not yet undergone postnatal catchup 
growth. This is further indicated by their lighter BW at 25 d. We speculate that our 
inability to effectively detect the impact of prenatal stress on body composition at 3 d of 
age is likely due to the decreased body mass of young lambs. In addition, we believe 
body composition estimates are more accurately represented as percentages of BW due to 
variability in lamb size and genetic potential.  
Our findings in wethers show that BIA estimates can also detect the impact of 
heat stress on body composition in rapidly-growing animals. Heat stress reduced average 
daily gain in wethers, as expected (Morrision et al., 1983), and our BIA-estimated lean 
mass values would indicate that this is due to a reduction in muscle growth, although 
equations estimating the collective mass of specific muscle groups were not able to detect 
heat stress-induced differences. It is worth noting that the moderate nature of heat stress-
induced effects in the present study was likely due to pair feeding of controls and thus 
differences represent direct effects of the heat stress itself. From these findings, we 
conclude that BIA estimates for FFM and FFST reasonably reflect stress-induced 
changes in body composition.  
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IMPLICATIONS 
Accurate live-animal body composition estimates will increase product uniformity 
and potentially reduce the risk of costly discounts that producers take at harvest for 
carcasses with low quality and low yield. BIA appears to be a potential tool for 
estimating carcass characteristics in live animals. Its relative simplicity and consistency 
mean that it could be adapted for use in livestock to improve efficiency and increase 
profits. Further studies will better optimize estimation equations for nutrient and body 
composition to increase precision and accuracy.  
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Table 4-1. Equations for carcass traits estimated from bioelectrical impedance analyses 
(BIA) in heat-stressed wethers and intrauterine growth-restricted (IUGR) neonatal lambs. 
Estimate Equation Citation 
   
 Live Animal BIA  
FFM1  = (0.585*BW) - (0.28*Rs) + (0.578*Xc) + 16.35  Berg & Marchello, ‘94 
FFM2 = (0.578*BW) - (0.293*Rs) + (0.039*L) +18.771  Berg & Marchello, ‘94 
FFM3 = (0.596*BW) - (0.286*Rs) + 19.711  Berg & Marchello, ‘94 
FFM4 = (0.643*BW) + (0.624*Xc) - 2.701  Berg & Marchello, ‘94 
  Berg & Marchello, ‘94 
FFST1 = (0.555*BW) - (0.247*Rs) + (0.390*Xc) + 16.260 Berg & Marchello, ‘94 
FFST2 = (0.542*BW) - (0.259*Rs) + (0.044*L) + 17.470 Berg & Marchello, ‘94 
FFST3 = (0.562*BW) - (0.251*Rs) + 18.529 Berg & Marchello, ‘94 
   
SUM = 1.7 + 0.338*BW - 0.0531*Rs + 0.0494*L Slanger et al. ‘94 
LSLRS = 1.7 + 0.237*BW - 0.0396*Rs + 0.0308*L Slanger et al. ’94 
LSL = 0.95 + 0.147*BW - 0.0329*Rs + 0.0222*L Slanger et al. ‘94 
   
Moisture = 0.66 + 0.94*XcD + 0.09*V Moro et al. ‘19 
Protein = -0.70 + 0.05*RsD + 0.03*V + 0.07*PA Moro et al. ‘19 
Fat = -2.11 + 0.10*RsD + 0.04*V Moro et al. ‘19 
Lean = -1.90 + 0.11*V + 0.18*RsD + 0.31*PA Moro et al. ‘19 
   
 Hot Carcass  
FFM1 = (0.454*BW) - (0.134*Rs) + (0.217*Xc) - (0.244*T) + 26.609 Berg & Marchello, ‘94 
FFM2 = (0.396*BW) - (0.106*Rs) + 20.216 Berg & Marchello, ‘94 
FFM3 = (0.437*BW) - (0.130*Rs) + (0.229*Xc) + 16.950 Berg & Marchello, ‘94 
  Berg & Marchello, ‘94 
FFST1 = (0.433*BW) + (0.124*L) - (0.114*Rs) + (0.175*Xc) -
(0.211*T)+17.811 
Berg & Marchello, ‘94 
FFST2 = (0.393*BW) - (0.089*Rs) + 17.773 Berg & Marchello, ‘94 
FFST3 = (0.419*BW) - (0.111*Rs) + (0.188*Xc) + (0.111*L) + 10.051 Berg & Marchello, ‘94 
   
SUM = -4.5 + 0.598*BW - 0.0297*Rs + 0.096*Xc + 0.114*L + 
0.103*T 
Slanger et al. ‘94 
LSLRS = -3.6 + 0.440*BW - 0.0214*Rs + 0.0880*Xc + 0.0527*L + 
0.0939*T 
Slanger et al. ’94 
LSL = -2.4 + 0.256*BW - 0.0142*Rs + 0.0521*Xc + 0.0327*L + 
0.0748*T 
Slanger et al. ‘94 
FFM, fat-free mass (kg); FFST, fat-free soft tissue (kg); SUM, sum of leg, sirloin, rack, shoulder, neck, 
riblets, shank, and lean trim (kg); LSLRS, sun of leg, sirloin, loin, rack, and shoulder; LSL, sum of leg, 
sirloin, and loin (kg); BW, bodyweight (kg); Rs, resistance (Ω); Xc, reactance (Ω); L, length between 
electrodes (cm); XcD, resistive density (kg2/ (cm2* Ω)); V, biometrical volume (cm2/ Ω); RsD, reactive 
density (kg2/ (cm2* Ω)); PA, phase angle (°); T, temperature (°C). 
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Table 4-2. Live animal composition estimated from bioelectrical impedance analysis 
(BIA) in intrauterine growth restricted lambs (IUGR) at 3 d and 25 d of age. 
Variables Control PI-IUGR 
PI-
IUGR+O2 MI-IUGR  P-value 
3 d of age       
BW, kg 5.0 ± 0.2a 2.6 ± 0.2b 4.6 ± 0.1a 3.9 ± 0.4c  0.02 
BW/BL, 
kg/cm 
0.018 ± 
0.001a 
0.011 ± 
0.001b 
0.017 ± 
0.001a 
0.017 ± 
0.002a 
 0.009 
       
FFM, kg 6.7 ± 0.3 7.1 ± 3.2 8.0 ± 1.7 6.9 ± 2.1  NS 
FFM/BW, 
kg/kg 1.4 ± 0.3 1.8 ± 0.3 1.7 ± 0.3 1.2 ± 0.3 
 NS 
       
Moisture, kg 6.1 ± 0.3a 3.2 ± 0.9b 6.3 ± 0.5a 4.7 ± 0.5c  0.008 
Protein, kg 1.52 ± 0.09 1.48 ± 0.65 1.87 ± 0.41 1.53 ± 0.45  NS 
Fat, kg - - - -  - 
Moisture/BW, 
kg/kg 
1.301 ± 
0.091 
1.362 ± 
0.503 
1.343 ± 
0.105 
1.226 ± 
0.068 
 NS 
Protein/BW, 
kg/kg 
0.321 ± 
0.021 
0.583 ± 
0.206 
0.398 ± 
0.083 
0.491 ± 
0.238 
 NS 
Fat/BW, kg/kg - - - -  - 
25 d of age      
BW, kg 11.8 ± 0.5a 9.1 ± 0.8b 11.4 ± 0.4a 9.2 ± 0.6b  0.002 
BW/BL, 
kg/cm 
0.024 ± 
0.001a 
0.024 ± 
0.002a 
0.023 ± 
0.002b 
0.021 ± 
0.001b 
 0.02 
       
FFM, kg 8.7 ± 0.6a 6.4 ± 0.7b 8.6 ± 0.8ac 7.4 ± 0.4bc  0.1 
FFM/BW, 
kg/kg 
0.82 ± 
0.04a 0.7 ± 0.04
b 0.82 ± 
0.04a 
0.81 ± 
0.04a 
 0.03 
       
Moisture, kg 7.4 ± 0.3a 5.9 ± 0.5b 7.9 ± 0.7a 6.7 ± 0.3b  0.04 
Protein, kg 
2.04 ± 
0.16a 
1.48 ± 
0.19b 
2.09 ± 
0.23a 
1.76 ± 
0.13b 
 0.1 
Fat, kg 0.97 ± 0.1a 0.31 ± 0.2b 1.23 ± 0.3a 0.65 ± 0.2b  0.03 
Moisture/BW, 
kg/kg 
0.653 ± 
0.042 
0.662 ± 
0.045 
0.702 ± 
0.059 
0.739 ± 
0.038 
 NS 
Protein/BW, 
kg/kg 
0.187 ± 
0.026 
0.164 ± 
0.013 
0.185 ± 
0.019 
0.193 ± 
0.011 
 NS 
Fat/BW, kg/kg 
0.086 ± 
0.012a 
0.031 ± 
0.021b 
0.108 ± 
0.022a 
0.069 ± 
0.016a 
 0.08 
Values are expressed as means ± SE; BW, bodyweight (kg); BL, body length (cm); 
FFM, fat-free mass (kg); PI-IUGR, placental insufficiency intrauterine growth 
restriction; MI-IUGR, maternal inflammation intrauterine growth restriction; NS, not 
significant;  
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Table 4-3. Live animal composition estimated from bioelectrical impedance analysis 
(BIA) in heat-stressed wethers on d14. 
Variables Control Heat Stress  P-value 
d 14     
BW, kg 47.4 ± 0.9 47.7 ± 0.9  NS 
ADG, kg 0.18 ± 0.02 0.13 ± 0.02  0.07 
     
FFM1, kg 36.6 ± 0.5 36.2 ± 0.8  NS 
FFM2, kg 39.2 ± 0.5 38.8 ± 0.7  NS 
FFM3, kg 39.6 ± 0.5 39.2 ± 0.7  NS 
FFM4, kg 28.7 ± 0.5 28.4 ± 0.9  NS 
FFM, kg 36.0 ± 0.5 35.7 ± 0.7  NS 
FFM1/BW 0.767 ± 0.009 0.770 ± 0.016  NS 
FFM2/BW 0.822 ± 0.009 0.823 ± 0.014  NS 
FFM3/BW 0.831 ± 0.008 0.832 ± 0.012  NS 
FFM4/BW 0.601 ± 0.008 0.603 ± 0.028  NS 
FFM/BW 0.700 ± 0.008 0.757 ± 0.017  NS 
     
FFST1, kg 35.8 ± 0.4 35.0 ± 0.7  NS 
FFST2, kg 37.4 ± 0.4 36.9 ± 0.7  NS 
FFST3, kg 37.9 ± 0.4 37.4 ± 0.7  NS 
FFST, kg 37.0 ± 0.4 36.6 ± 0.7  NS 
FFST1/BW 0.751 ± 0.008 0.754 ± 0.014  NS 
FFST2/BW 0.783 ± 0.008 0.786 ± 0.013  NS 
FFST3/BW 0.794 ± 0.008 0.796 ± 0.011  NS 
FFST/BW 0.776 ± 0.008 0.778 ± 0.016  NS 
     
SUM 18.2 ± 0.2 17.9 ± 0.4  NS 
LSLRS 13.1 ± 0.2 12.9 ± 0.3  NS 
LSL  7.8 ± 0.1 7.7 ± 0.2  NS 
SUM/BW 0.382 ± 0.002 0.382 ± 0.002  NS 
LSLRS/BW 0.274 ± 0.001 0.274 ± 0.003  NS 
LSL/BW 0.165 ± 0.001 0.165 ± 0.001  NS 
Values are expressed as means ± SE; FFM, fat-free mass (kg); FFST, fat-free soft 
tissue (kg); SUM, sum of leg, sirloin, rack, shoulder, neck, riblets, shank, and lean trim 
(kg); LSLRS, sum of leg, sirloin, loin, rack, and shoulder; LSL, sum of leg, sirloin, and 
loin (kg); BW, bodyweight (kg); NS, not significant; 
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Table 4-4. Carcass characteristics estimated from bioelectrical impedance analysis 
(BIA) in heat-stressed wethers at necropsy.   
Variables Control Heat Stress  P-value 
Necropsy      
BW, kg 48.1 ± 0.8 48.3 ± 1.1  NS 
ADG, kg 0.11 ± 0.01 0.08 ± 0.01  0.08 
     
FFM1, kg 25.9 ± 0.5 24.9 ± 0.8  NS 
FFM2, kg 20.7 ± 0.5 19.4 ± 0.8  NS 
FFM3, kg 21.9 ± 0.5 20.9 ± 0.7  NS 
FFM4, kg 23.1 ± 0.5 20.1 ± 0.9  0.01 
FFM, kg 22.9 ± 0.4 21.4 ± 0.8  0.1 
FFM1/BW 1.063 ± 0.009 1.026 ± 0.017  0.03 
FFM2/BW 0.850 ± 0.010 0.798 ± 0.015  0.004 
FFM3/BW 0.900 ± 0.009 0.861 ± 0.013  0.02 
FFM4/BW 0.948 ± 0.009 0.829 ± 0.030  <0.001 
FFM/BW 0.940 ± 0.008 0.878 ± 0.018  0.003 
     
FFST1, kg 23.1 ± 0.4 22.1 ± 0.7  NS 
FFST2, kg 21.7 ± 0.3 19.2 ± 1.1  0.05 
FFST3, kg 19.8 ± 0.4 18.7 ± 0.7  NS 
FFST, kg 21.5 ± 0.4 20.1 ± 0.7  0.08 
FFST1/BW 0.949 ± 0.008 0.912 ± 0.015  0.04 
FFST2/BW 0.900 ± 0.012 0.789 ± 0.045  0.04 
FFST3/BW 0.811 ± 0.008 0.774 ± 0.012  0.01 
FFST/BW 0.883 ± 0.008 0.825 ± 0.017  0.004 
     
SUM 16.3 ± 0.2 16.2 ± 0.4  NS 
LSLRS 11.2 ± 0.1 11.2 ± 0.3  NS 
LSL  6.6 ± 0.1 6.6 ± 0.2  NS 
SUM/BW 0.667 ± 0.002 0.668 ± 0.002  NS 
LSLRS/BW 0.454 ± 0.001 0.460 ± 0.003  NS 
LSL/BW 0.270 ± 0.001 0.272 ± 0.001  NS 
Values are expressed as means ± SE; FFM, fat-free mass (kg); FFST, fat-free soft 
tissue (kg); SUM, sum of leg, sirloin, rack, shoulder, neck, riblets, shank, and lean trim 
(kg); LSLRS, sun of leg, sirloin, loin, rack, and shoulder; LSL, sum of leg, sirloin, and 
loin (kg); BW, bodyweight (kg); NS, not significant; 
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Table 4-5. Nutrient composition estimated from bioelectrical impedance analysis 
(BIA) in heat-stressed wethers at trial day 0 and 14. 
Variables Control Heat Stress  P-value 
d 0     
Moisture, kg 7.4 ± 0.3 7.9 ± 0.5  NS 
Protein, kg 3.1 ± 0.1 3.0 ± 0.1  NS 
Fat, kg 3.9 ± 0.2 3.7 ± 0.2  NS 
Lean, kg 12.0 ± 0.4 11.9 ± 0.4  NS 
Moisture/BW 0.159 ± 0.005 0.177 ± 0.1  NS 
Protein/BW 0.067 ± 0.001 0.068 ± 0.001  NS 
Fat/BW 0.086 ± 0.002 0.083 ± 0.001  NS 
Lean/BW 0.260 ± 0.004 0.267 ± 0.005  NS 
d 14      
Moisture, kg 7.2 ± 0.5 7.4 ± 0.7  NS 
Protein, kg 3.3 ± 0.1 3.3 ± 0.1  NS 
Fat, kg 4.4 ± 0.2 4.1 ± 0.2  NS 
Lean, kg 12.8 ± 0.4 12.8 ± 0.4  NS 
Moisture/BW 0.151 ± 0.009 0.157 ± 0.014  NS 
Protein/BW 0.069 ± 0.001 0.069 ± 0.001  NS 
Fat/BW 0.091 ± 0.002 0.088 ± 0.001  NS 
Lean/BW 0.267 ± 0.005 0.272 ± 0.006  NS 
Values are expressed as means ± SE; BW, bodyweight; NS, not significant; 
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